Roxadustat  Protocol FGCL -4592 -059 Amendment 2  
FibroGen, Inc.  1 Confidential  CLINICAL STUDY PROTOCOL  
STUDY TITLE:  Open -Label Extension Study to Evaluate the Efficacy and 
Safety of  FG-4592 for the Long- Term Maintenance 
Treatment of Anemia in Dialysis  and Non- Dialysis Patients 
with Chronic Kidney Disease 
PROTOCOL NUMBER:  FGCL -4592-059 
SPONSOR:  FibroGen, Inc.  
409 Illinois Street 
San Francisco, California 94158 United States  
IND NUMBER:  74,454 
STUDY DRUG:  Roxadustat 
INDICATION:  Anemia associated with Chronic Kidney Disease or End-Stage R enal D isease  
FIBROGEN MEDICAL 
MONITOR:  Name:   
Title:  
Telephone:  
Mobile:  
E-mail:
PROTOCOL VERSION/DATE:  Original Protocol: 06 March 2012
Amendment No. 1: 31 October 2013 Amendment No. 2: 25 July 2018 
CONF
IDENTIALITY STATEMEN T
The information contained in this document is confidential and proprietary to FibroGen, Inc. No 
part of this document or any of the information contained herein may be transmitted,  disclosed, 
shared, reproduced, published or utilized by any persons without prior written authorization by 
FibroGen, Inc.  NCT #  [STUDY_ID_REMOVED]

Roxadustat  Protocol FGCL -4592 -059 Amendment 2  
FibroGen, Inc.  2 Confidential  
    INVESTIGATOR SIGNATURE PAGE  
STUDY ACKNOWLEDG EMENT  
 
An Open -Label Extension Study to Evaluate the Efficacy and Safety of F G-4592 for the Long-
Term Maintenance Treatment of Anemia in Dialysis  and Non- Dialysis Patients with  Chronic 
Kidney Disease  
FGCL -4592- 059 
Amendment No. 2  
25 July 2018  
INVESTIGATOR STATEMENT  
I have read the protocol, including all appendices  and the current Investigator ’s Brochure  (IB) , 
and I agree that it contains all necessary details for me and my staff to conduct this study as 
described.  I will conduct this study as outlined herein and will make a reasonable effort to 
complete the study w ithin the time designated.  
I will provide all study personnel under my supervision copies of the protocol and access to all information provided by FibroGen, Inc. I will discuss this material with the m to ensure that they 
are fully informed about the drugs  and the study.  
I will conduct  the trial in accordance with the guidelines of Good Clinical Practice (GCP) 
including the archiving of essential documents , the Declaration of Helsinki, any applicable local 
health authority, and Institutional Review Board/Independent Ethics Committee  (IRB/IEC) 
requirements.  
 
   
 
Investigator Name (Printed)   Institution  
 
   
Signature   Date  
Roxadustat  Protocol FGCL -4592 -059 Amendment 2  
FibroGen, Inc.  3 Confidential  
    SUMMARY OF MAJOR PROTOCOL AMENDMENT CHANGES  
Amendment 2  
In addition to the major changes affecting study conduct listed below, minor editorial changes were 
made throughout the document to correct typographical errors and to improve consistency and 
clarity.  
Description of Change  Rationale for Change  Section(s) 
Affected  
The treatment period was changed from 
260 weeks (5 years) to up to 312 weeks 
(6 years). Subjects enrolled in the study prior to Amendment 2 may continue treatment for up to an additional 1 year 
or a maximum of 6 years.  
New subjects enrolled under Amendmen t 
2 will receive treatment for 52 week.  The increased treatment duration of 
up to 6  years allows the collection of 
long-term efficacy and safety data, 
and gives subjects previously enrolled 
in other roxadustat Phase 2/3 studies the option of continuing tre atment 
with roxadustat . Synopsis  
Section 4.1
Appendix  A  
Instructions were added for roxadustat  
starting doses, and initial visit frequency, 
for subjects who received blinded study 
treatment in their previous study  To allow subject enrollment without 
the need to unblind.  Synopsis 
Sections 
4.3.1   
4.3.2  
10.2 
Appendix  A  
Appendix  B  
Dose adjustment algorithm, and 
maximum per -kg dose was adjusted.  To align with global phase 3 program.  Synopsis 
Section  
4.3.2  
Appendix  C  
 
Data Monitoring Committee review will 
end after last meeting of the global 
Phase 3 program.  To align with global phase 3 program.  Sections  
4.6 
10.4  
HMP: aligned with text from Phase 3 
programs  To align with global phase 3 program.  Section  
4.5.1  
Table  1  
The compound designation of “FG -4592” 
was replaced with “roxadustat” throughout, except in the title of the 
study.  The generic name of “roxadustat” is 
now available. The compound name 
was not changed in the title of the 
protocol as that is the name the trial 
was origin ally registered.  Entire 
Document  
Roxadustat  Protocol FGCL -4592 -059 Amendment 2  
FibroGen, Inc.  4 Confidential  
    TABLE OF CONTENTS  
INVESTIGATOR SIGNATURE PAGE  .........................................................................................2  
SUMMARY OF MAJOR PROTOCOL AMENDMENT CHANGES  ...........................................3  
LIST OF ABBREVIATIONS  ..........................................................................................................8  
PROTOCOL SYNOPSIS  ..............................................................................................................10  
1. INTRODUCTION  ......................................................................................................15  
1.1. Epidemiology of Chronic Kidney Disease (CKD) and End- Stage Renal 
Disease (ESRD)  ..........................................................................................................15  
1.2. Anemia Associated with Chronic Kidney Disease  .....................................................15  
1.3. Treatment of Anemia  ..................................................................................................16  
1.4. Rationale for HIF Prolyl Hydroxylase Inhibi tors to Treat Anemia  ............................16  
1.5. Roxadustat as Therapy for Anemia  ............................................................................17  
1.6. Clinical Experience with Roxadustat  ..........................................................................17  
1.6.1.  Pharmacokinetics and Pharmacodynamics  .................................................................18  
1.6.2.  Efficacy  .......................................................................................................................18  
1.6.3.  Safety  ..........................................................................................................................20  
1.6.4.  Summary  .....................................................................................................................20  
1.7. Rationale for Subject Population ................................................................................20  
1.8. Rationale for Dose Selection  ......................................................................................21  
2. OBJECTIVES  .............................................................................................................23  
2.1. Primary Objective  .......................................................................................................23  
2.2. Secondary Objectives  .................................................................................................23  
2.3. Exploratory Objectives  ...............................................................................................23  
3. ENDPOINTS AND ASSESSMENTS  ........................................................................24  
3.1. Efficacy  .......................................................................................................................24  
3.2. Safety  ..........................................................................................................................24  
3.3. Select biomarkers  ........................................................................................................24  
4. STU DY DESIGN  .......................................................................................................25  
4.1. Description of the Study .............................................................................................25  
4.1.1.  Control Groups  ...........................................................................................................25  
4.2. Randomization and Treatment Assignment  ................................................................25  
4.2.1.  Randomization Procedures  .........................................................................................25  
4.2.2.  Treatment Assignment  ................................................................................................25  
Roxadustat  Protocol FGCL -4592 -059 Amendment 2  
FibroGen, Inc.  5 Confidential  
    4.3. Study Treatment  ..........................................................................................................26  
4.3.1.  Dose and Schedule  ......................................................................................................26  
4.3.2.  Dose Adjustments  .......................................................................................................26  
4.4. Concomitant Medications, Procedures and Nondrug Therapies  ................................27  
4.4.1.  Concomitant Medications  ...........................................................................................27  
4.4.2.  Contraception  ..............................................................................................................27  
4.4.3.  Rescue Medication  ......................................................................................................27  
4.4.4.  Excluded (Prohibited) Medications/Therapies/Substances  ........................................28  
4.5. Safety Plan  ..................................................................................................................28  
4.5.1.  Hepatic Safety Monitoring .........................................................................................29  
4.6. Data Monitoring Committee  .......................................................................................30  
5. ELIGIBILITY CRITERIA  .........................................................................................31  
5.1. Inclusion Criteria  ........................................................................................................31  
5.2. Exclusion Criteria  .......................................................................................................31  
6. STUDY DRUG/TREATMENT SUPPLY .................................................................32  
6.1. FibroGen Investigational Product  ...............................................................................32  
6.1.1.  Formulation of roxadustat ...........................................................................................32  
6.1.2.  Storage of Study Drug  ................................................................................................32  
6.1.3.  Administration of Study Drug  ....................................................................................32  
7. STUDY PROCEDURES  ............................................................................................33  
7.1. Study Procedures by Visit  ..........................................................................................33  
7.1.1.  Treatment Period  ........................................................................................................33  
7.2. Post-Treatment Follow -Up Period ..............................................................................36  
7.3. Missed Visits  ..............................................................................................................36  
7.4. Unscheduled Visits  .....................................................................................................36  
7.5. Assessments ................................................................................................................36  
7.5.1.  Central Laboratory  ......................................................................................................36  
7.5.2.  Local Laboratory  ........................................................................................................38  
7.5.3.  Vital Signs  ..................................................................................................................38  
7.5.4.  Electrocardiogram  .......................................................................................................38  
7.5.5.  Quality of Life Questionnaire  .....................................................................................38  
8. SUBJECT DISCONTINUATION  ..............................................................................39  
9. STUDY TERMINATION BY FIBROGEN  ...............................................................40  
Roxadustat  Protocol FGCL -4592 -059 Amendment 2  
FibroGen, Inc.  6 Confidential  
    10. STATISTICS  ..............................................................................................................41  
10.1.  Sample Size Determination  ........................................................................................41  
10.2.  Treatment Assignment  ................................................................................................41  
10.3.  Analysis Population  ....................................................................................................41  
10.4.  Interim Analysis  ..........................................................................................................41  
10.4.1.  Subject Enrollment and Disposition  ...........................................................................41  
10.5.  Replacement of Subjects  .............................................................................................42  
10.6.  Statistical Analysis  ......................................................................................................42  
10.6.1.  Demographics and Baseline Characteristics  ...............................................................42  
10.6.2.  Efficacy Analyses  .......................................................................................................42  
10.6.3.  Exploratory Analyses  ..................................................................................................43  
10.6.4.  Safety Analyses  ..........................................................................................................43  
10.7.  Statistical Analysis Plan  .............................................................................................43  
11. SAFETY  .....................................................................................................................44  
11.1.  Background  .................................................................................................................44  
11.2.  Definitions  ..................................................................................................................44  
11.2.1.  Definition of an Adverse Event  ..................................................................................44  
11.2.2.  Definition of an Adverse Reaction .............................................................................44  
11.2.3.  Definition of a Suspected Adverse Reaction  ..............................................................44  
11.2.4.  Definition of a Serious Adverse Event  .......................................................................45  
11.3.  Procedures for Eliciting, Recording, and Reporting Adverse Events  ........................45  
11.3.1.  Adverse Event Reporting Period ................................................................................45  
11.3.2.  Assessing Adverse Event Severity  .............................................................................45  
11.3.3.  Assessing Relationship of Adverse Event to Study Drug  ..........................................46  
11.3.4.  Reporting Serious Adverse Events on the SAE Report Form  ....................................47  
11.3.5.  Pregnancies: Reporting and Follow -up of Subjects  ....................................................48  
11.3.6.  Abnormal Laboratory Findings  ..................................................................................48  
12. STUDY MONITORING  ............................................................................................49  
12.1.  Data Quality Assurance  ..............................................................................................49  
12.2.  Compliance with Laws and Regulations  ....................................................................49  
12.3.  Data Collection and Handling ....................................................................................50  
13. HUMAN SUBJECTS  .................................................................................................51  
13.1.  Ethical Considerations  ................................................................................................51  
Roxadustat  Protocol FGCL -4592 -059 Amendment 2  
FibroGen, Inc.  7 Confidential  
    13.2.  Communication with the Institutional Review Board or Independent Ethics 
Committee  ...................................................................................................................51  
13.3.  Informed Consent Form  ..............................................................................................51  
13.4.  Subject Confidentiality  ...............................................................................................51  
14. INVESTIGATOR REQUIREMENTS  .......................................................................53  
14.1.  Study Medication Accountability  ...............................................................................53  
14.2.  Disclosure of Data  ......................................................................................................53  
14.3.  Retention of Records  ..................................................................................................53  
15. PUBLICATION POLICY ..........................................................................................54  
16. REFERENCES  ...........................................................................................................55  
APPENDIX A.  SCHEDULE OF STUDY ASSESSMENTS  .....................................................57  
APPENDIX B.  DOSING FOR SUBJECTS PREVIOUSLY TREATED WITH 
PLACEBO  ..................................................................................................................59  
APPENDIX C.  DOSE ADJUSTMENT GUIDELINES FOR ROXADUSTAT  ........................60  
 
LIST OF TABLES  
Table 1:  Summary of investigator actions with respect to Hepatic Monitoring .......................29  
 
Roxadustat  Protocol FGCL -4592 -059 Amendment 2  
FibroGen, Inc.  8 Confidential  
    LIST OF ABBREVIATIONS  
AE adverse event  
ALP alkaline phosphatase  
ALT alanine aminotransferase  
AST aspartate aminotransferase  
AUC  area under the curve for plasma concentration vs. time  
BIW twice weekly  
BP blood pressure  
CBC  complete blood count(s)  
CFR Code of Federal Regulations  
CHr reticulocyte hemoglobin content  
CKD  chronic kidney disease  
Cmax maximum concentration of drug after dosing  
CRF case report form  
CRP  C-reactive protein  
CYP-450 cytochrome P -450 isoenzyme s 
DMC  Data Monitoring Committee  
DNA  deoxyribonucleic acid  
ECG  electrocardiogram  
EE Efficacy Evaluable (population)  
eGFR  estimated glomerular filtration rate  
EPO  erythropoietin  
ESA erythropoiesis -stimulating agent  
ESRD  end-stage renal disease  
ET early termination (visit)  
FACT -An Functional Assessment of Cancer Therapy -Anemia  
FDA Food and Drug Administration  
GCP  Good Clinical Practice  
GGT  gamma -glutamyl transferase  
Hb hemoglobin  
hCG human chorionic gonadotropin  
HD hemodialysis  
HDL high-density lipoprotein  
HIF hypoxia -inducible factor  
HIF-PH HIF prolyl hydroxylase  
HIPAA  Health Insurance Portability and Accountability Act  
HMP  Hepatic Monitoring Plan  
HR heart rate  
hs-CRP  high sensitivity C -reactive protein  
IB Investigator’s Brochure  
ICF informed consent form  
ICH International Conference on Harmonization  
IEC Independent Ethics Committee  
IND Investigational New Drug Application  
INR international normalized ratio (for anticoagulant monitoring)  
IRB Institutional Review Board  
IV intravenous  
Ki inhibition constant  
Roxadustat  Protocol FGCL -4592 -059 Amendment 2  
FibroGen, Inc.  9 Confidential  
    LDL low-density lipoprotein  
LFT liver function test  
LOCF  last-observation -carried forward  
max maximum  
min minimum  
MedDRA  Medical Dictionary for Regulatory Activities  
N number of subjects  
NCI National Cancer Institute  
NCI-CTCAE  NCI Common Terminology Criteria for Adverse Events  
OSD  Oral Solid Dosage  
PD peritoneal dialysis  
PH prolyl hydroxylase  
PK pharmacokinetic(s)  
PT prothrombin time  
QT time interval between Q and T waves in an ECG  
QW once weekly  
RBC  red blood cell  
SAE serious adverse event  
SAP Statistical Analysis Plan  
sTfR  soluble transferrin receptor  
t1/2 terminal elimination half -life 
Tbili total bilirubin  
TIBC  total iron binding capacity  
TIW three times weekly  
TSAT  transferrin saturation  
ULN upper limit of normal  
US United States  
USRDS  United States Renal Data System  
VEGF  vascular endothelial growth factor  
WBC  white blood cell  
Roxadustat  Protocol FGCL -4592 -059 Amendment 2  
FibroGen, Inc.  10 Confidential  
    PROTOCOL SYNOPSIS  
Study Title:  An Open -Label Extension Study to Evaluate the Efficacy and Safety of 
FG-4592 for the Long- Term Maintenance Treatment of Anemia in 
Dialysis  and Non -Dialysis Patients with  Chronic Kidney Disease  
Protocol Number:  FGCL -4592 -059 
Investigational 
Product:  Roxadustat  
Target Population:  Dialysis and non -dialysis chronic kidney disease ( CKD ) subject s who 
have  completed the treatment period of  an roxadustat  study  in the U.S.  
IND Number:  74,454  
Study Phase:  Open -label extension   
Study Centers 
Planned:  Up to 20 study centers in the U.S.  
Number of Subjects 
Planned:  Up to 50 subjects  
Primary Objective:  To evaluate the long -term efficacy and safety of  roxadustat in the 
maintenance of hemoglobin (Hb) in dialysis  and non- dialysis subjects 
with CKD  
Secondary Objectives:  Evaluate  roxadustat  doses and dose adjustments  
Exploratory 
Objectives:  Assess the effect of  roxadustat  on iron utilization parameters  
Assess the effect of  roxadustat  on select biomarkers  
Study Design:  This is an open -label, long -term maintenance study of  roxadustat 
anemia therapy in dialysis and non- dialysis subjects with CKD who 
have completed the treatment perio d of an roxadustat anemia study in 
the U.S.  
Subjects enrolled in this study prior to Amendment 1 may continue for 
an additional  52 weeks (1 year) or a total of 8 years of treatment.  
Subjects enrolled under Amendment 2 will be treated for up to 52 
weeks (1 year).  
Subjects who received roxadustat in a previous study will return for 
study visits every 4 weeks until the end of the treatment period.  
Subjects who received placebo in their previous study will return for study visits weekly, for the first 4 weeks, and every other week, until 
week 24 ( Appendix  C), followed by every 4 weeks until the end of the 
treatment period.  
Subjects who received placebo in their previous study  will receive 
roxadustat according to their weight as described in Appendix  B. 
If treatment assignment is blinded at the time of enrollment, if the subject  has been on a stable dosing regimen for at least 2 months prior  
to the switch and if the last dose is lower than the starting doses 
described in Appendix  B, the subject may continue on the current 
dosing regimen.  
After the end of treatment (defined as last day the subject receives 
study drug) the subject will return for a follow -up visit 4 weeks later.  
The baseline Hb value for efficacy analysis is defined as the mean of 
the central laboratory Hb value from the baseline visit at Day 1 (prior to 
receiving the first dose of study drug in this study), plus any other central lab Hb values within 15 days prior to Day 1.  
Safety will be assessed by vital signs, physical examinations, clinical 
laboratory values (includin g liver function tests [LFTs] and complete 
blood counts [CBC]), electrocardiograms (ECGs), and adverse event 
(AE) and concomitant medication reporting.  Clinical laboratory tests, 
including LFTs and Hb levels, may be assessed at additional, 
unscheduled visi ts for safety reasons.  
Roxadustat  Protocol FGCL -4592 -059 Amendment 2  
FibroGen, Inc.  11 Confidential  
    Rescue Medication : 
If a subject is not responding adequately to roxadustat,  and rescue 
therapy is considered a medical necessity by the investigator, rescue 
therapy will be allowed for a subject provided this has been discussed 
with the study medical monitor, or is deemed to be an immediate 
medical necessity by the investigator.  
The three options for rescue therapy are as follows:  
Blood Transfusion: For subjects requiring a blood transfusion, administration of study medication may continue.  
Iron Supplementation:  Oral iron should be the first -line option for iron 
supplementation.  Intravenous (IV) iron supplementation may be 
considered if the following criteria are met:  
The subject has not responded adequately to 2 or more 
dose increases or reached the maximum dose limit and  
Ferritin saturation is <50 ng/ml or transferrin saturatio n 
(TSAT) is <10%  
OR 
The subject is intolerant of oral iron therapy and  
Ferritin saturation is <50 ng/ml or TSAT is <10%  
 roxadustat  treatment should continue during IV and oral iron 
supplementation.  The investigator may discontinue IV iron 
supplementation once he no longer considers the subject to be iron 
deficient. The investigator should carefully monitor the subject’s Hb 
response after IV iron supplementation.  
Erythropoiesis -stimulating agents (ESAs): ESAs are not to be 
concurrently administered with roxadustat  . Once a subject is 
considered a treatment failure due to a lack of efficacy and/or lack of 
tolerability of  roxadustat  , and ESA treatment is initiated per the treating 
physician,  roxadustat  must be permanently discontinued and the 
subject is to be discontinued from the study.  In the event of an 
extenuating circumstance during which a subject inadvertently receives 
an ESA for a short period of time (e.g., recent bleeding, disruption of  
roxadustat dosing due to hospitalization or vacation, etc. ) the study 
medical monitor should be contacted to evaluate the appropriateness of 
continuing treatment with roxadustat . 
Dose Adjustments for Roxadustat  
Dose adjustments will occur  according to Appendix  C. All subjects in 
the roxadustat arm will be dosed orally TIW during the Treatment Period.  During the course of the study, the dose and the dosing 
frequency may be changed to optimize efficacy and toler ability  based 
on the clinical judgment of the investigator and study medical monitor. The maximum roxadustat dose is 3.0 mg/kg per dose or 400 mg, 
whichever is lower.  
All dose adjustments as well as assessments of excessive 
hematopoiesis are based on Hb va lues using a point -of-care device 
such as HemoCue® or CritLine®. In the event that the central lab Hb 
value of the site visit is significantly different and the dose adjustment 
decision based on the HemoCue® or CritLine® value is being 
reconsidered, the Medical Monitor should be contacted, if possible.  
The determination of Hb response is based on the central laboratory Hb 
value.  
Dose adjustment reviews will occur on Week 4, and at intervals of 
every 4 weeks thereafter (Weeks 8, 12, 16, etc.) except in the event of 
excessive hematopoiesis, in which case doses may be adjusted at any 
Roxadustat  Protocol FGCL -4592 -059 Amendment 2  
FibroGen, Inc.  12 Confidential  
    time. In such cases, dose adjustment reviews are resumed at 4 -week 
intervals. For example, if the subject’s Hb increases >2.0 g/dL from 
Week 1 to Week 3, the subject’s dose is reduced by one dose step at 
Week 3. The next dose adjustment review should occur 4 weeks later 
at Week 7 and at 4- week intervals thereafter.  
If the dose adjustment interval falls on a non- study visit week (starting 
Week 4), the dose adjustment review should be  performed at the next 
scheduled clinic visit, if a dose adjustment was not required at the 
previous visit. For example, if a subject’s visit is scheduled for Weeks 6 
and 8, and the dose adjustment would occur at Week 7, then the dose 
adjustment should be evaluated at the Week 8 visit.  
For subjects on prolonged dose- hold,  with stable (not dropping)  Hb, the 
Investigator  may use discretion  to schedule less frequent visits. Anytime 
Hb is assessed via HemoCue®/CritLine®/local lab, a central lab Hb 
should be obtained as well.  
Excessive Hematopoiesis  
For subjects randomized to Roxadustat, the following scenarios are defined as “excessive hematopoiesis” ;  
Hb increases by > 2.0 g/dL at any time within a 4 week  period: reduce 
the dose by one dose step.  
Hb reaches or exceeds 13 g/dL: hold dosing, check Hb weekly. Resume dosing when Hb < 12.0 g/dL, at a dose that is reduced by two 
dose steps.  
Roxadustat  Protocol FGCL -4592 -059 Amendment 2  
FibroGen, Inc.  13 Confidential  
    Inclusion Criteria  Minimum a ge 18 years  
Subjects who have completed the treatment period of an ongoing  
roxadustat  anemia study  in the U.S.  
Exclusion Criteria:  Subjects assigned to epoetin alfa in a previous  roxadustat  anemia 
study  in the U.S.  
Pregnant or breastfeeding females  
Females of childbearing potential, unless using contraception as 
detailed in the protocol; male subjects with sexual partners of 
childbearing potential who are not on birth control unless the male subject agrees to use contraception  
Subjects who received roxadustat  in the previous study that did not 
demonstrate adequate hemoglobin response in the investigator’s clinical judgment  
Any medical condition that in the opinion of the investigator may pose a safety risk to a subject in this study , or which may interfere with study 
participation  
Study Peri ods:  There will be t wo study periods:  
Treatment:  Subjects will be dosed up to 416 weeks  (6 years) . Subjects 
enrolled under Amendment 2 will be dosed for 52 weeks (1 year)  
Post-treatment follow -up: 4 weeks . 
Study Procedures:  See Schedule of Study Assessments  (Appendix  A) 
Investigational 
Product, Dose, and Mode of 
Administration:  Subjects will receive 20, 50, and 100 mg of roxadustat  as an oral solid 
dosage (OSD) . All OSDs  must be administered whole.  
Initial Doses  
Subjects who received roxadustat in a previous study will continue to 
receive roxadustat  at the same dose and dosing frequency  (three times 
weekly [TIW], twice weekly [BIW], o r once weekly [QW]  as they 
received at the end of their last study, unless a dose adjustment is 
required. Subjects who received placebo in their previous study will 
start treatment with roxadustat  according to their weight as described in 
Appendix  B. 
If treatment assignment is blinded at the time of enrollment, the subject 
has been on a stable dosing regimen for at least 2 months prior to the 
switch and if the last dose is lower than the starting doses described in Appendix  B, the subject may continue on the current dosing regimen.  
Dose Adjustment Rules  
Guidelines for dose adjustments are provided in Appendix  A.  
 
Efficacy Endpoints and 
Assessments:  Mean monthly Hb values over time  
Number (%) of subject s maintaining monthly (defined as a 4- week 
interval) mean Hb at ≥ 10 g/dL during study participation upon correction 
(defined as having achieved two consecutive Hb values of ≥ 10 g/dL)  
Number (%) of subject s maintaining Hb between 10- 13 g/dL  for at least 
60% of scheduled Hb assessments after the first Hb value is 10 g/dL or 
higher  
Composite rate of summarized rescue therapy events (transfusions, IV iron, ESAs) and rate of individual rescue therapy events  
Number (%) of subjects with phlebotomies  
Roxadustat weekly total doses over time  
Dose adjustment frequencies  
Hb variab ility  
Number (%) of subjects withdrawn from the study due to inadequate 
efficacy  
Safety Assessment s:  Vital signs, clinical laboratory values, and changes in physical 
examinations  
AEs and serious adverse events (SAEs)  
Roxadustat  Protocol FGCL -4592 -059 Amendment 2  
FibroGen, Inc.  14 Confidential  
    Exploratory Laboratory  
Evaluations:  Collect the following labs only if a baseline value is available for the 
subject (i.e., test was done prior to start of study drug treatment in 
previous  roxadustat  study):   
Reticulocyte hemoglobin content ( CHr); 
High sensitivity C -reactive protein (hs -CRP);  
Hepcidin levels in serum;  
Additional  biomarkers .  
Statistical Methods:  All subjects who have received any dose of study treatment will be 
included in the safety analyses.  The efficacy p opulation will include all 
subjects who receive any study treatment and have non- missing Hb 
measurement at Baseline and at least one non- missing post -baseline 
Hb measurement.  
Monthly mean Hb values will be computed based on the average of Hb 
values within a 4-week period, and Hb data will be summarized 
accordingly over time.  
Hb values within 28 days of known gastrointestinal bleeding, substantial 
surgical blood loss, or receipt of rescue therapy of IV iron, red blood cell 
(RBC) transfusion, or ESA, will be censored in efficacy analysis.  A last -
observation- carried- forward (LOCF) method may be used to impute any 
missing Hb values.   
Continuous endpoints will be summarized descriptively by number of 
subjects (N), mean, standard deviation, median, minimum (min), and 
maximum (max) values.  
Categorical endpoints will be summarized descriptively by count and percentage.  
Safety data will be tabulated using descriptive statistics.  
This study will be conducted in accordance with the guidelines of Good Clinical Practice (GCP) and the 
applicable regulatory requirement(s), including the archiving of essential documents.  
Roxadustat  Protocol FGCL -4592 -059 Amendment 2  
FibroGen, Inc.  15 Confidential  
    1. INTRODUCTION 
1.1. Epidemiology of Chronic Kidney Disease (CKD) and End -Stage Renal Disease 
(ESRD)  
Chronic kidney disease (CKD) is a growing worldwide public health challenge associated with 
significant morbidity and mortality that is both underdiagnosed and undertreated. It is 
characterized by the progressive loss of kidney function, ultimately resulting in end stage renal disease (ESRD) with the need for  renal replacement therapy (kid ney transplant or dialysis), or 
premature death.  In 2007, CKD affected 13% of the United States (U.S.) adult population, or 
approximately 29 million adults, and its prevalence is growing rapidly ( Coresh, 2007) . All-cause 
mortality risk has been recognized to increase exponentially as CKD stages advance (Tonelli,  2006) . The number of people suffering from ESRD continues to increase worldwide, 
with the US having one of the world’s highest prevalence rates with 1,700 cases for every million in the general population ( USRDS, 2009) . In 2007, there were 527,000 ESRD patients in 
the US, of whom 341,000 were on hemodialysis (HD), 26,000 were on peritoneal dialysis (PD), and 159,000 had received a kidney transplant; 71, 000 were on the transplant waiting list 
(USRDS, 2009) . The expected remaining lifetime of a dialysis patient is 5.9 years, compared 
with 16.4 years for a transplant patient, and 25.2 years for someone of comparable age in the general population ( USRDS, 2009) . The prevalence of ESRD is estimated to grow to 774,000 by 
the year 2020 (USRDS , 2009) . 
1.2. Anemia Associated with Chronic Kidney Disease 
Anemia, or decreased circulating red blood cell (RBC) mass, is a common complication in patients with CKD.  Although the pathogenesis of anemia is multifactorial, decreased production 
of endogenous eryt hropoietin (EPO), a hormone produced primarily in the kidney, is considered 
its main etiological agent in patients with CKD.  Other factors may include the shortened lifespan 
of RBCs, the presence of infection and inflammation, and iron and other nutritiona l deficiencies 
(Remuzzi, 2000) . Anemia may be present in the early stages of CKD, and its prevalence 
increases with the progressive deterioration of kidney function. In ESRD, anemia is present in 
over 90% of patients ( Kausz, 2002) . 
It is estimated that there are approximately 1.1 million adult patients in the US with CKD Stages 3b–5 and a hemoglobin (Hb) level <11.0 g/dL. In 2008, at initiation of dialysis, patients had an 
average Hb level of 9.9 g/dL. Approximately 75% of patients had Hb <11.0 g/dL and many had anemia that was significantly more severe: 48% had Hb <10.0 g/dL, and 25% had Hb <9.0 g/dL (USRDS, 2008) . 
The main impact of anemia on organ function is the reduction of oxygen delivery to tissues, leading to fatigue and effort intolerance. Other consequences, such as impaired cognitive 
function, sleep disorder, altered hemostasis , depressed immune function, and impaired cardiac 
function, are not uncommon. Multiple studies have shown benefits in treating anemia in terms of reduction in RBC transfusion requirements, reductions in morbidity and mortality risks, and possible improveme nt in health -related quality of life ( NKF K/DOQI, 2007) . 
Roxadustat  Protocol FGCL -4592 -059 Amendment 2  
FibroGen, Inc.  16 Confidential  
    1.3. Treatment of Anemia  
Today, therapy with an erythropoiesis -stimulating agent (ESA) is a major alternative to 
transfusion in managing anemia associated with CKD.  For those not resistant to ESAs, parenteral 
administration of exogenous recombinant human erythropoietin (epoetin al fa or beta) or 
pegylated analogues has been a widely accepted approach for treatment of anemia in patients 
with CKD ( Eschbach, 1987; Eschbach, 1989; Winearls, 1986) , despite the documented safety 
risks.  These safety risks include hypertension and thrombosis, and may be associated with the 
supraphysiologic plasma EPO levels frequently observed with ESA therapy. Anemic patients 
with CKD or ESRD will require life -long treatment with these agents.  
There is currently an unmet medical need for a convenient oral treatment that will correct anemia in CKD non- dialysis and dialysis patients to a target Hb level that is safe and well tolerated.  An 
ESA dose relationship to mortality has been reported: higher mortality rates in ESRD patients targeting a higher Hb were reported in the Normal Hematocrit  Study ( Besarab, 1998)  and a 
review of the USRDS database ( Zhang, 2004) . Therefore, a treatment option that avoids 
supraphysiologic levels of circulating plasma EPO levels may be a safer alternative.  
Furthermore, ESA therapy for anemia in ESRD patients on HD usually requires concomitant intravenous (IV) iron supplementation therapy. R oxadustat is an oral medication that will 
potentially deliver effective treatment for CKD related anemia with l ess need for iron 
supplementation and without producing supraphysiologic levels of circulating EPO. 
1.4. Rationale for HIF Prolyl Hydroxylase Inhibitors to Treat Anemia 
Virtually all tissues depend on a sufficient supply of oxygen for survival. Lack of oxygen 
associated with hypoxic, ischemic, and anemic conditions triggers a series of homeostatic 
responses. Hypoxia -inducible factor (HIF) is a transcription factor believed to be the key element 
in the body’s oxygen sensing mechanism ( Semenza, 2000) . HIF regulates expression of genes 
that modulate both the acute and chronic response to hypoxia, and HIF -responsive genes regulate 
a wide range of processes, including erythropoiesis, iron metabolism, oxidation, cellular metabolism, glycolysis, vasculogenesis, cell cycle progression, and apoptosis. Chronic hypoxia and intermittent hypoxia induce different sets of genes associated with HIF transcriptional activity ( Fan, 2005 ). 
HIF is a heterodimeric transcription factor family comprising three oxygen -sensitive isoforms 
(HIF 1 α, HIF -2α and HIF -3α) and a constitutively expressed HIF -1β subunit. Each heterodimeric 
isoform is responsible for the induction of specific sets of genes (Greijer, 2005; Hu, 2003) . For 
example, HIF -1α has bee n shown to regulate vascular endothelial growth factor (VEGF) 
expression ( Buchler, 2003; Gray, 2005) , while HIF 2α  is critical for the induc tion of the EPO 
gene and erythropoiesis ( Scortegagna, 2005; Warnecke, 2004) . The expression of HIF target 
genes occurs when the active heter odimer binds to a conserved deoxyribonucleic acid (DNA) 
motif, termed the hypoxia response element, found within all target genes, and which in cooperation with other co- activators initiates de novo transcription.  One of the most sensitive and 
well-studied HIF -responsive genes is the EPO gene. Increased transcription of the EPO gene 
leads to increased circulating levels of EPO, which acts at sites of erythropoiesis to enhance the differentiation and proliferation of RBC precursors. 
Although HIF -α isoforms a re constitutively produced, they fail to accumulate under normoxic 
conditions, due to recruitment and binding of the Von Hippel -Lindau protein, which targets HIF -
Roxadustat  Protocol FGCL -4592 -059 Amendment 2  
FibroGen, Inc.  17 Confidential  
    α isoforms for degradation through the ubiquitin proteasom e pathway.  The molecular mechanism 
for oxygen- dependent degradation of HIF -α is based on the hydroxylation of specific proline 
residues, as catalyzed by a family of HIF prolyl hydroxylases (HIF -PH) that utilize molecular 
oxygen as the substrate for hydroxylation. Thus, HIF -PH constitutes the  body’s main oxygen 
sensor by regulating the prevalence and activity of nuclear HIF protein. Under hypoxic 
conditions, HIF PHs are inactive and lead to initiation of the HIF -responsive transcriptional 
cascade ( Semenza, 1998 ; Wang, 1995) . 
The treatment of anemia with HIF -PH inhibitors, by stimulating a broad range of physiological 
mechanisms of erythropoiesis in vivo, has the potential to address significant unmet medical 
needs and largely avoid the ESA -related adverse effects, thus significantly improving patient 
outcomes. Anemia management using a HIF -PH inhibitor is expected to increase Hb levels more 
physiologically with much lower plas ma EPO concentrations than those associated with 
exogenous parenteral ESA administration in anemia therapy.  
1.5. Roxadustat as Therapy for Anemia 
Roxadustat is a potent and reversible HIF -PH inhibitor that transiently induces HIF stabilization, 
and leads to a functional HIF transcriptional response that elevates EP O gene expression and 
circulating levels of EPO.  The reversible inhibition of HIF -PH enzymes and induction of HIF 
transcription mimics the erythropoietic response associated with exposure of humans to intermittent hypoxia.  This response is not limited to increases in endogenous EPO production; 
rather, it is a coordinated response that also results in transcription of genes for proteins necessary in iron metabolism.  In contrast to the classical paradigm  suggesting that anemia in 
CKD patients is caused by the inability of these patients to produce EPO, studies with roxadustat in CKD suggest that the kidneys of subjects with CKD can produce sufficient EPO for robust erythropoiesis. Yet, the median plasma E PO levels resulting from dosing of  roxadustat for the 
treatment of anemia in subjects with CKD and ESRD are within the physiologic range and are lower than the supraphysiologic levels associated with ESA therapy.  
Roxadustat also has the potential to effect ively treat anemia caused by inflammation -induced 
functional iron deficiency, which is typically unresponsive to ESA. A number of inflammatory mediators reduce iron availability for erythropoiesis. Because HIF -PH inhibitors such as  
roxadustat increase expr ession not only of the EPO gene but also of genes regulating iron 
metabolism, it is postulated that roxadustat  may be effective treatment for anemia.  
1.6. Clinical Experience with Roxadustat  
Roxadustat is currently being studied in dialysis and non- dialysis subjects with CKD and anemia.  
Several Phase 1 and 2 clinical studies in the U.S., Europe, and Asia have been completed. Preliminary and final information from these studies is provided below and in the most recent Investigator’s Brochure.  
As of 7 September 2013, 1197 subjects have been enrolled in roxadustat  clinical studies and 969 
subjects have been exposed to roxadustat. The 377 healthy subjects and 592 dialysis and non-dialysis subjects with CKD who have been treated with roxadustat in these studies contri buted to 
an estimated total roxadustat  exposure of 127 patient -years.  Up to 24 weeks of  roxadustat  dosing, 
in doses of up to 3.0 mg/kg, have been administered to subjects with CKD, a subset of which have been treated for up to 2 years in this open- label ex tension study. In completed Phase 1 
studies, healthy subjects received single doses of roxadustat  up to 4.0 mg/kg and repeat doses up 
Roxadustat  Protocol FGCL -4592 -059 Amendment 2  
FibroGen, Inc.  18 Confidential  
    to 3.75 mg/kg three times a week for 4 weeks. In a completed thorough QT study in healthy 
subjects, single doses up to 5 m g/kg were administered, without evidence of QT prolongation. 
The clinical data collected thus far suggest that roxadustat is  generally safe and well tolerated in 
healthy adult subjects, and in dialysis and non- dialysis subjects with anemia and CKD.  
1.6.1. Pharmac okinetics and Pharmacodynamics  
The pharmacokinetics (PK) and pharmacodynamics of  roxadustat  were characterized in studies 
in healthy subjects and in dialysis and non- dialysis subjects with CKD.  The PK profile of 
roxadustat  was generally dose proportional ( except at the lowest dose of 0.3 mg/kg); terminal 
elimination half -life (t1/2) was 12 to 14 hours in healthy subjects, and 15 to 19 hours in dialysis 
subjects (after a single 1 and 2 mg/kg dose).  
With an intermittent dose regimen (once weekly [QW], twice w eekly (BIW), or three times 
weekly [TIW]), no or limited accumulation in the mean area under the curve for plasma 
concentration vs. time (AUC) or maximum concentration of drug after dosing (Cmax) was observed. Furthermore, no evidence was found for time -dependent pharmacokinetics (no auto-
induction or inhibition). Roxadustat is highly protein bound and the PK of  roxadustat is not 
affected by dialysis. Metabolites found in urine suggested Phase 2 metabolism as the major metabolic pathway.  In plasma, parent  roxadustat is the main component. In vitro data suggest 
that the inhibitory potential of  roxadustat on cytochrome P -450 isoenzymes (CYP) is limited, and 
the most potent inhibition constant (Ki) value was observed for CYP 2C8 (16 μM). In a clinical drug- drug interaction study with rosiglitazone, a probe drug for CYP 2C8, roxadustat  did not 
show any inhibitory potential on CYP 2C8 in vivo. 
In healthy adult male subjects (Study FGCL -SM4592- 016), roxadustat administered orally as a 
single dose up to 4.0 mg/kg, a nd as multiple doses, QW, BIW, or TIW for 4 weeks at doses up to 
3.75 mg/kg, was pharmacodynamically active as evidenced by dose -dependent transient 
increases in endogenous EPO (starting from single doses of 0.3 mg/kg), increases in 
reticulocytes (starting  from doses of 2 mg/kg), and Hb responses (starting at 3 mg/kg). The mean 
peak level of plasma EPO following the Day 26 dose of 2.0 mg/kg TIW was 326.3 ± 197.0 mIU/mL.  
In pharmacodynamic studies conducted with roxadustat  in CKD subjects not on dialysis (Study 
FGCL 4592- 017), the mean maximum EPO increase from baseline ranged from 82 443 mIU/mL 
and 492- 554 mIU/mL after a single 1 and 2 mg/kg dose, respectively. In dialysis subjects (Study 
FGCL -4592- 039), comparable dose -dependent increases in EPO levels were observed, both pre -
dialysis and post -dialysis.  These increases in endogenous EPO were transient and the effect 
disappeared within approximately 48 hrs. 
In contrast, EPO levels associated with therapeutic ESA dosing range from 1,500 to over 10,000 
mIU/mL (Besarab, Frinak, and Yee 131 -42). The reported mean administered individual ESA 
dose in a meta- analysis of subjects undergoing HD in 2005 was 8,000 IU, which would 
correspond to plasma EPO Cmax levels exceeding 3,000 mIU /mL (Fishbane and Besarab 1274-
82). This is approximately 10- fold higher than the physiologic range.  
1.6.2. Efficacy  
Data from a 4 -week dose ranging study in anemic subjects with CKD not on dialysis (Study 
FGCL -SM4592- 017) suggest that  roxadustat  promotes erythropoiesis at lower doses in subjects 
Roxadustat  Protocol FGCL -4592 -059 Amendment 2  
FibroGen, Inc.  19 Confidential  
    with CKD than in healthy subjects. With 0.7 mg/kg TIW dosing, mean Hb increased by 1.0 g/dL 
over a 6 -week period in anemic subjects with CKD who completed 4 weeks of dosing; greater 
mean Hb increases of 2.0 to 2.3 g/dL oc curred at  roxadustat doses of 1.5 and 2.0 mg/kg TIW, 
respectively.  Hemoglobin responder (Hb increase of ≥ 1.0 g/dL) rates were 62%, 60%, 91%, and 
100% in the  roxadustat cohorts receiving 0.7, 1.0, 1.5, and 2.0 mg/kg TIW, respectively. The Hb 
responses were also greater at the higher  roxadustat doses (1.5 to 2.0 mg/kg) in the BIW dosing 
groups. With the add itional criterion that Hb achieve a level of ≥11 g/dL as well as increasing by 
≥1.0 g/dL, the Hb responder rate at 2.0 mg/kg of  roxadustat  IW and TIW was 8 9% and 91%, 
respectively.  The rapid rates of rise in Hb with  roxadustat treatment were not accomp anied by 
elevations in blood pressure (BP), as has been reported with ESA treatment (Eschbach et al. 992-1000). 
Data from a 16 to 24- week treatment Phase 2b st udy in subjects with CKD not on dialysis (Study 
FGCL -4592- 041) showed that absolute and weight -based doses of  roxadustat, administered TIW 
and BIW, effectively corrected and maintained Hb levels to a Hb target of 11 g/dL (range of 11-
13 g/dL in 96 subjects  and 10.5- 12.0 g/dL in 48 subjects).  
Data from 48 HD and 12 PD subjects enrolled in a 12- week incident -dialysis study (Study 
FGCL -4592- 053), using similar tiered, weight -based initial doses as study FGCL 4592- 041, 
indicate increases in mean Hb of approxima tely 2 g/dL after six weeks of treatment.  Subjects 
were randomized to receive no iron, oral iron or IV iron. The Hb responses were indistinguishable between the oral and IV iron arms; subjects in the no iron arm had a similar Hb response during the first 8 weeks of treatment which plateaued during the last 4 weeks of treatment, suggesting that with long- term roxadustat treatment, iron supplementation may be 
necessary. However, data suggest that supplementation with oral iron is as effective as IV iron, and is recommended as the first -line option for iron supplementation in the Phase 3 studies. 
Starting  roxadustat doses between 1.0 and 1.6 mg/kg appeared adequate to correct Hb in these 
subjects.  
Data from a US study in subjects with ESRD on dialysis treated f or 6 and 19 weeks suggest that 
subjects receiving a stable ESA dose can be converted to treatment with  roxadustat (Study 
FGCL -4592- 040). During the 6- week dose portion of this study subjects who switched from 
epoetin alfa to  roxadustat had a dose -dependent  Hb response. The 1.0 mg/kg roxadustat dose was 
comparable to the Epoetin alfa control, which had a small decline in Hb level from baseline and a lower percent Hb responder rate compared to the higher doses of  roxadustat. The 1.5 and 2.0 
mg/kg roxadustat dose arms resulted in a Hb increase of about 1 g/dL from baseline and an 89% response rate, more than double that of the Epoetin alfa arm, despite the absence of IV iron supplementation. Regression slope analyses of Hb values over time showed that the estim ated 
rate of Hb rise was positive and statistically significant for the 1.5 mg/kg and 2.0 mg/kg dose cohorts, with a Hb increase of 0.22 g/dL (p=0.0040) and 0.18 g/dL (p=0.0146) per week, respectively.  In the 19- week portion of the study, during which dose -titration was allowed, Hb 
maintenance was demonstrated to be durable in  roxadustat treatment arms (combined) over the 
treatment period.  In contrast, the Hb levels of epoetin alfa controlled subjects appeared to decline 
gradually over time despite steady l evels of epoetin alfa doses, possibly because IV iron was not 
permitted during the treatment period. Efficacy of  roxadustat was confirmed in a similarly 
designed 6- week study conducted in ESRD subjects in China. 
Preliminary data taken at the time of this p rotocol amendment from an ongoing open label 
extension study (Study FGCL -4592- 059, to which some subjects from Studies FGCL -4592- 041 
Roxadustat  Protocol FGCL -4592 -059 Amendment 2  
FibroGen, Inc.  20 Confidential  
    and FGCL -4592 -040 rolled over) further suggest the durability of  roxadustats effect in 
maintaining Hb levels in CKD subject s for up to 2 years.  
1.6.3. Safety  
The overall frequency and type of treatment -emergent adverse events (TEAEs) and serious 
adverse events (SAEs) observed in these clinical studies reflect events that would be expected to 
occur in CKD subjects with multiple co -morbidities and on a number of concomitant 
medications.  There has been no SAE attributable by the sponsor to the use of roxadustat . Safety 
analyses did not reveal any association between the rates of occurrence of cardiovascular events 
with roxadustat , or any effect on AE rates related to either increasing Hb levels or on the rate of 
change of Hb levels.  
Adverse event rates of hypertension (1% in Study FGCL -SM4592- 017, 7.6% in Study FGCL -
4592- 041, and 10% FGCL -4592- 053) and serious adverse events of arteriovenous -fistula 
thrombosis (overall incidence in dialysis -dependent CKD subjects: 2%), compare favorably with 
the rates reported in published ESA studies in similar subject populations (Krapf and Hulter 470-80;Fishbane and Besarab 1274- 82). No safety risks wer e associated with increased rate of rise of 
Hb levels or with achieving a Hb level above 11 g/dL using roxadustat. Although Study FGCL -
4592- 041 subjects achieved Hb>11 g/dL in 52% of exposure time during study, no 
cardiovascular safety events (death, MI, s troke, unstable angina, hospitalization for congestive 
heart failure, or hospitalization for arrhythmias) were reported while Hb>11 g/dL during treatment with  roxadustat. 
No increased cancer risk has been noted with roxadustat treatment; however, the study program was not powered to detect absence of cancer risk.  
Liver enzymes were monitored closely throughout the  roxadustat clinical development program. 
Increases in liver enzymes were infrequently seen, and  were generally mild and transient in 
nature.  No cases of Hy’s Law were observed throughout the program. An independent data and 
safety monitoring committee concluded that there was no concern for hepatotoxicity with roxadustat.  
Based on the safety data co llected to date,  roxadustat has an acceptable safety profile that 
supports its further development. 
1.6.4. Summary  
Data from 18 completed and ongoing studies suggest that  roxadustat exhibits dose -dependent 
PK, binds well with protein, and is not filtered out duri ng HD. Intermittent dosing with 
roxadustat results in transient activation of HIF, intermittent induction of endogenous 
physiologic -range EPO, and dose -dependent erythropoiesis, suggesting a coordinated mechanism 
of erythropoiesis that is different from ES A therapy, including beneficial effects on iron 
handling. The clinical data collected thus far suggest that  roxadustat is generally safe and well 
tolerated in dialysis and non- dialysis subjects with CKD and anemia when treated with  
roxadustat for up to 2 years.  
1.7. Rationale for Subject Population  
In Phase 1 studies of healthy subjects in Europe, the US, and Japan, roxadustat was generally well tolerated, and resulted in a dose -dependent pharmacodynamic response leading to increased 
Roxadustat  Protocol FGCL -4592 -059 Amendment 2  
FibroGen, Inc.  21 Confidential  
    circulating EPO and reticulo cyte levels.  Data from a Phase 2a study (FGCL -SM4592- 017) in the 
US in Stage 3 or 4 CKD non- dialysis subjects indicate that roxadustat is well tolerated and 
results in significant increases in Hb levels in such subjects.  A Phase 2b study (FGCL -4592 -041) 
in a similar CKD non -dialysis subject population has been completed, as are a Phase 2 study 
(FGCL -4592 -053) in newly initiated ESA -naïve dialysis subjects, and a Phase 2 study (FGCL -
4592- 040) in a dialysis subject population that was previously receiving EPO . These studies 
showed that FG 4592 was effective throughout the continuum of CKD/ESRD:  the correction of 
anemia in CKD non- dialysis subjects, the correction of anemia in newly initiated ESA -naïve 
ESRD dialysis subjects, and the maintenance of Hb in ESRD dialysis subjects.  
Since progression of CKD into ESRD inexorably leads to an increased progression and 
likelihood of anemia, treatment of anemia in CKD is expected to be chronic, unless the patient successfully receives a renal transplant.  It is, therefore, important to evaluate the long- term 
efficacy, safety, and tolerability of  roxadustat in the treatment of anemia in such patients. 
Eligible subjects enrolled in an ongoing U.S. roxadustat anemia study, who have completed the treatment period, will be offered participation in this long- term extension study. 
1.8. Rationale for Dose Selection  
Starting doses of roxadustat were studied in three ways in the Phase 2 program: using a strict weight -based dosing approach that was useful in the proof of concept s tage; using a tiered 
weight -based approach where a subject’s starting dose was selected based on categorizing the 
subject’s body weight as low (45 to < 70 kg), medium (70 to 100 kg), or heavy (> 100 kg); and using an absolute starting dose regardless of body weight. The tiered weight -based approach has 
been chosen for the development of roxadustat in the Phase 3 program to provide a practical starting dose strategy for a controlled Correction to target Hb values, based on the observed 
relationship between body weight, PK, and Hb response, and the requirements of oral dosing. 
The tiered, weight -based starting doses selected for this study consist of the following roxadustat 
doses: 70, and 100 mg, for low weight (≤ 70 kg), and high weight (> 70 to 160 kg) subj ects, 
respectively. These dose tiers are based primarily on the interi m safety and efficacy data 
generated in the CKD nondialysis Correction of anemia study (FGCL -4592- 041) and confirmed 
by the dialysis study. These doses will be administered at a frequenc y of TIW. Using this dosing 
scheme, subjects will receive starting roxadustat doses between 0.9 mg/kg TIW for the heaviest 
subject, and 1.6 mg/kg TIW for the lightest subject. This is comparable to the starting doses of  
1.0 to 1.6 mg/kg, which were the dos es that effectively corrected Hb levels in studies FGCL -
4592- 041 and FGCL -4592- 053. Further dose adjustment to achieve Correction and subsequent 
Maintenance is based upon regular monitoring of Hb. 
Based on the Phase 2 data, it is expected that subjects who receive these starting doses to correct 
anemia will be able to maintain Hb levels with a total weekly dose reduction of the order of 22 to 35%. This dose reduction can be achieved by adjusting the per dose amount towards the protocol -defined Hb target ran ge. The Phase 2 studies evaluated the need for dose adjustments 
for both Hb Correction and Hb Maintenance. Dose adjustments were allowed at regular 4- week 
intervals to maintain, increase, or decrease the dose according to prespecified rules. Pre -specified 
dosing steps were used to correct and maintain Hb levels within treatment thresholds based on absolute Hb levels and change of Hb in the previous 4 weeks. Additional rules for dose adjustment were provided to minimize excessive hematopoiesis. These dose adjustment rules 
Roxadustat  Protocol FGCL -4592 -059 Amendment 2  
FibroGen, Inc.  22 Confidential  
    were successful in Hb Correction and Hb Maintenance and will be adopted in this study with 
minor modifications.  
Roxadustat  Protocol FGCL -4592 -059 Amendment 2  
FibroGen, Inc.  23 Confidential  
    2. OBJECTIVES  
2.1. Primary Objective  
Evaluate the long- term efficacy and safety of roxadustat in the maintenance of Hb in dialysis and 
non-dialysis CKD subjects.  
2.2. Secondary Objectives  
Evaluate roxadustat doses and dose adjustments. 
2.3. Exploratory Objectives  
• Assess the effect of roxadustat on iron utilization parameters;  
• Assess the effect of roxadustat on select biomarkers. 
Roxadustat  Protocol FGCL -4592 -059 Amendment 2  
FibroGen, Inc.  24 Confidential  
    3. ENDPOINTS AND ASSESS MENTS  
3.1. Efficacy  
The efficacy endpoints in this study are:  
• Mean monthly Hb values over time;  
• Number (%) of subjects maintaining monthly (monthly defined as a 4- week interval) 
mean Hb at ≥10 g/dL during study participation upon correction (correction is defined 
as having achieved 2 consecutive Hb values of ≥10 g/dL);  
• Number (%) of subjects maintaining Hb between 10- 13 g/dL for at least 60% of 
scheduled Hb assessments after the first Hb value is 10 g/dL or higher.  
• Composite rate of summarized rescue therapy eve nts (transfusions, IV iron, ESAs) 
and rate of individual rescue therapy events;  
• Number (%) of subjects with phlebotomies;  
• Roxadustat weekly total doses over time;  
• Dose adjustment frequencies;  
• Hb variability; 
• Number (%) of subjects withdrawn from the study due to inadequate efficacy.  
3.2. Safety  
Safety in this study will be assessed by evaluating the following:  
• Vital signs, clinical laboratory values, ECG, and changes in physical examinations;  
• AEs and SAEs.  
3.3. Select biomarkers  
Exploratory assessments in this study will evaluate the following parameters:  
• Reticulocyte hemoglobin content (CHr);  
• Highly sensitive C -reactive protein (hs -CRP);  
• Hepcidin levels in serum;  
• Additional exploratory biomarkers.  
Roxadustat  Protocol FGCL -4592 -059 Amendment 2  
FibroGen, Inc.  25 Confidential  
    4. STUDY DESIGN  
4.1. Description of the Study  
This is an open- label, lon g-term maintenance study of  roxadustat anemia therapy in dialysis and  
non-dialysis subjects with CKD who have completed the t reatment period of an roxadustat  
anemia study in the U.S . Up to 50 non- dialysis , HD, and PD subjects will be enrolled in this 
study from up to 20 study centers  throughout the U.S. 
Subjects who received  roxadustat  in a previous  study will continue to receive roxadustat  at the 
same dose and frequency as they received at the end of the treatment period in their previous 
study, unless a dose adjustment is required.  
Subjects who received placebo in their previous study may start treatment with  roxadustat at 
starting doses according to their weight ( Appendix  B). 
Subjects will receive study treatment for up to 312 weeks ( 6 years). Subjects enrolled in this 
study prior to Amendment 2 may continue treatment for up to an additional 1 year of treatment.  
Subjects who received roxadustat in a previous study will return for study visits every 2 weeks for the first 104 weeks of treatment (including time on previous Phase 2/3 studies of roxadustat), and every 4 weeks thereafter, until the end of the treatment period. 
Subjects who received placebo in their previous study will return for study visits weekl y until 
their Hb level has stabilized to a range of 10.0 to 1 2.0 g/dL (±2.0 g/dL) through 4 consecutive 
weeks. These s ubjects will then return for study visits every 2 weeks for the first 24 weeks of 
treatment, followed by every 4 weeks until the end of the treatment period.  
After the end of treatment (defined as the last day a subject receives study drug) the subject will 
return  for a  follow -up visit 4 weeks later . 
The baseline Hb value for efficacy analysis is defined as the mean of the central laboratory  Hb 
value from the b aseline v isit at  Day 1 (prior to receiving the first dose of study drug in this 
study), plus any other central lab Hb values within 15 days prior to Day 1.  
Safety will be assessed by vital signs, physical examinations, clinical laborato ry values 
(including liver function tests [LFTs] and complete blood counts  [CBC] ), electrocardiograms 
(ECGs), AE s and concomitant medication reporting. Clinical laboratory tests, including LFTs 
and Hb levels, may be assessed at additional times on unscheduled visits for safety reasons.  
4.1.1. Control Groups  
No control group will be included in this study.  
4.2. Randomization and Treatment Assignment  
4.2.1. Randomization Procedures  
No randomization will be performed for this study. 
4.2.2. Treatment Assignment  
Subjects who received  roxadustat  in a previous  study will continue to receive roxadustat . 
Roxadustat  Protocol FGCL -4592 -059 Amendment 2  
FibroGen, Inc.  26 Confidential  
    Subjects who received placebo in their previous study may start treatment with  roxadustat . 
The roxadustat oral solid dosage (OSD) will be supplied  in an open- label manner to all subjects . 
4.3. Study Treatment  
4.3.1. Dose and Schedule  
Subjects who received  roxadustat  in a previous study will continue to receive roxadustat  at the 
same dose and dosing frequency (TIW, BIW, or QW)  as they received at the end of thei r last 
study, unless a dose adjustment is required.  
Subjects who received placebo in their previous study will receive roxadustat by weight category 
as described in Appendix  B. 
If treatment assignment is blinded at the time of enrollment, the subject has been on a stable 
dosing regimen for at least 2 months and if the last dose is lower than the starting doses 
described in Appendix B , the subject may continue on the current dosing regimen. 
4.3.2. Dose Adjustment s 
Guidelines for dose adjustments are provided in C. In general:  
• The Hb thresholds for dose adjustments are < 10 g/dL for dose increases and 
> 12 g/dL for dose reductions  
• Dose adjustment rules are based on ch anges in Hb values over 4 weeks  and whether 
the Hb target has been reached or exceeded . 
• Dose increases and decreases  are pre -set at the dose steps described in Appendix A . 
• The maximum dose is 3.0 mg/kg. 
• The time interval between dose adjustment reviews should be 4 weeks, except in the 
event of excessive hematopoiesis  (when the subject’s dose should be reduced), or 
rapidly declining Hb (when the subject’s dose should be increased) . For example, 
even if a subject’s dose is not increased or decreased following a dose adjustment 
review visit, the next dose adjustment revi ew will be 4 weeks after the last dose 
adjustment review.  
• For subjects who received placebo in their previous study, no dose adjustment will occur from Weeks 1 through 4 except in the event of excessive hematopoiesis or rapidly declining Hb.  
• For s ubjects w ho received roxadustat, or blinded study drug, and on a stable dose for 
the past 2 months, in a previous study, dose adjustment review will occur  4 weeks  
from the last dose adjustment review in the previous study. 
• During the course of t he study, the dose a nd the dosing frequency may  be changed to 
optimize efficacy and tolerability  based on the  clinical judgment of the investigator 
and study medical monitor. 
Roxadustat  Protocol FGCL -4592 -059 Amendment 2  
FibroGen, Inc.  27 Confidential  
    In the event of an extenuating clinical circumstance (e.g., recent bleeding, disruption of dosing 
due to hospitalization or vacation, etc.), the investigator may dose a subject outside of the dose 
adjustment parameters provided this has been discussed with the study medical monitor. 
Dose Frequency Adjustments should be done according to Appendix C . 
Dose Adjustment for Excessive Hematopoiesis  
At any time during the treatment period, if Hb increases by > 2.0 g/dL in 2 weeks that is not due 
to an RBC transfusion the dose should be reduced by one dose step ( Appendix A ). 
If there are clinical concerns for a subject’s excessively high Hb value  outside the dose 
adjustment intervals  (as described in Appendix A ), the investigator may adjust the dose  
immediately; the investigator may also decid e to perform a therapeutic phlebotomy in addition to 
the dose adjustments —these situations should be documented and discussed with the study 
medical monitor whenever possible.  
4.4. Concomitant Medications , Procedures and Nondrug Therapies  
4.4.1. Concomitant Medication s 
Concomitant medications are any prescription or over -the-counter preparations (including herbal 
products and “natural remedies”) used by a subject while participating in this clinical trial.  
For all concomitant medication use, the study site must provide an indication for its use. If the 
stated indication is a nonspecific condition, e.g., “rash,” documentation of the condition, as 
specific as possible, must be provided by the subject’s primary care physician and maintained in the subject’s clinical  study records as source documentation. 
4.4.2. Contraception  
Female subjects of childbearing potential must agree to  use a medically acceptable form of birth 
control (e.g., oral contraceptive  pills , depot  progesterone, or intrauterine device). The above list 
is not comprehensive. Abstinence alone suffices as adequate contraception.  Male subjects with 
sexual partners of childbearing potential who are not using birth control (as described above) must use contraception (e.g., condom) if not surgically sterile (i.e., vasectomy).  Contraceptive 
methods must be practiced from the time informed consent is signed and through at least 
1 month after the last dose of study drug.  
4.4.3. Rescue Medication  
If a subject is not responding adequately to roxadustat, and rescue therapy is considered a 
medical necessity by the investigator , rescue therapy will be allowed for a subject provided this 
has been discussed with the study medical monitor, or is deemed to be an immediate medical necessity by the investigator. 
The three options for  rescue therapy are as follows:  
1. Blood t ransfusion: For subjects undergoing rescue therapy with transfusion, 
administration of study medication may continue. 
2. Iron s upplementation: Oral iron should be the first -line option for iron supplementation. 
IV iron suppl ementation may be considered if the following criteria are met: 
Roxadustat  Protocol FGCL -4592 -059 Amendment 2  
FibroGen, Inc.  28 Confidential  
    • The subject has not responded adequately to 2 or more dose increases or reached the 
maximum dose limit and  
• Ferritin saturation is <50 ng/ml or  transferrin saturation (TSAT) is <10%  
OR 
• The subject is intolerant of oral iron therapy and  
• Ferritin saturation is <50 ng/ml or TSAT is <10%  
Roxadustat treatment should continue during oral and IV iron supplementation. The investigator may discontinue IV iron supplementation once he no longer considers the subject to be iron deficient. The investigator should carefully monitor the subject’s Hb response after the IV iron supplementation. 
3. ESAs : ESAs are not to be concurrently administered with. Once a subject is considered a 
treatment failure due to a lack of efficacy and/or lack of tolerability, and ESA treatment is initiated per the treating physician , roxadustat must  be permanently  discontinued and the 
subject also is to be discontinued from the study. In the event of an extenuating 
circumstance during which a subject inadvertently receives an ESA for a short period of time (e.g., recent bleeding, disruption of dosing due to hospital ization or vacation, etc. ), 
the study medical monitor should be contacted t o evaluate the appropriateness of 
continuing treatment with  roxadustat.  
4.4.4. Excluded ( Prohibited) Medications/Therapies/Substances  
Subjects are not permitted to consume more than three alcohol -containing drinks per day during 
the Treatment or Follow -up Periods . 
Concomitant therapy with any of the following is prohibited:  
• Androgen, deferoxamine, deferiprone, or deferasirox therapy until completion of the 
study 
• Red blood cell transfusion until completion of the study, unless used as rescue 
therapy  
• Intravenous iron supplementation, unless used as rescue therapy  
• Any ESA therapy until completion of the study, unless used as rescue therapy 
• Dapsone, or chronic acetaminophen use > 2.0 g/day or > 500 mg per dose repeated every 6 hours, from the week 1 visit until completion of the study 
• Use of herbal medicine is strongly discouraged during the course of the study. If a subject insists on starting use of an herbal medicine during the study, this should be discussed with the study medical monitor on a case -by-case basis  
4.5. Safety Plan  
Safety will be assessed throughout the study. A baseline profile of each subject will be established through clinical laboratory values  (serum chemistry and LFTs, CBCs, iron studies, 
and pregnancy status) , physical assessments, and ECGs. During the course of the study, vital 
signs, complete and targeted physical assessments, laboratory tests (CBC with differential, serum 
Roxadustat  Protocol FGCL -4592 -059 Amendment 2  
FibroGen, Inc.  29 Confidential  
    chemistry, serum iron studies, and special laboratory tests), and ECGs will be performed at 
specific intervals.  Any medically significant changes from baseline will be monitored throughout 
the study and appropriate interventions will be made accordingly. Clinical laboratory tests , 
including LFTs  and Hb levels , may be assessed at additional times on unscheduled visits for 
safety  reasons . 
Adverse events, SAEs, and ongoing concomitant medica tion usage will be monitored and 
recorded throughout  the study. Serious adverse event reports will be evaluated individually to 
assess the impact of the event, if any, on the overall safety of the product and on the study itself. Cumulative AEs will be mon itored throughout the study. All SAEs and AEs will be followed 
until resolved, stable, or until the subject’s final v isit. See Section  11 for details on AE and SAE 
reporting.  
Subjects will be closely monitored for inadequate or excessive hematopoiesis, which will be managed according to guidelines stipulated in the protocol  and based on protocol -defined dose 
adjustment  rules ( Section  4.3.2) and reasons for study drug discontinuation. Liver function will 
also be closely monitored and investigators will follow the Hepatic Monitoring Plan (HMP; described in Section  4.5.1)  to determine when heightened surveillance is required and what 
actions, if any, are needed with study drug adminis tration.  
4.5.1. Hepatic Safety Monitoring  
The guidelines described  in this section are intended to enable early detection and action  
following abnormal liver function test (LFT) results. It is the responsibility of the Investigator  
to expeditiously review LFTs, f ollow  these guidelines and  contact the Medical Monitor if a  
study subject meets any of the LFT abnormalities specified below.  In addition, repeat LFTs 2 
to 3 times weekly, then weekly or less until abnormalities stabilize or  return  to within normal 
limits. LFTs should include the usual 4: ALT, AST, Tbili and ALP  
Table  1: Summary of investigator actions with respect to Hepatic Monitoring  
Repeat LFT s within 2 to 3days if:  Discontinue Study Drug if:  
• ALT or AST > 3 x ULN, or 
• Tbili > 2 x ULN  • ALT or AST >  8 x ULN, or 
• ALT or AST >  5 x ULN for  > 2 weeks, or 
• ALT or AST >  3 x ULN and (Tbili > 2 x ULN 
or INR > 1.5), or 
• ALT or AST >  3 x ULN with appearance of 
fatigue, nausea,  vomiting, right  upper 
quadrant  pain or  tenderness,  fever, rash,  
and/or  eosinophilia  (> 5%) 
Abbreviations: ALP =  alkaline  phosphatase; ALT = alanine aminotransferase;  AST = aspartate aminotransferase;  
GGT =  gamma -glutamyl transferase;  INR = international normalized ratio; LFT = liver function test;  Tbili = total 
bilirubin;  ULN =  upper limit of normal.  
If close monitoring for LFTs in a subject is not possible, study drug should be discontinued 
Evaluate the subject for potential causes, which  may include the following:  
• Detailed history of symptoms and prior or concurrent diseases  
• Concomitant drug use, including nonprescription medications, herbal and dietary 
supplements, alcohol or recreational drug use, or s pecial diets  
• Exposure to environmental chemical agents  
Roxadustat  Protocol FGCL -4592 -059 Amendment 2  
FibroGen, Inc.  30 Confidential  
    • Rule out acute viral hepatitis Types A, B, C, D,  E; autoimmune or alcoholic hepatitis; 
nonalcoholic steatohepatitis; hypoxic/ischemic hepatopathy; biliary tract disease  
• Obtain additional tests as appropriate: eg, INR, GGT or direct bilirubin; ultrasound or  
other imaging to assess biliary tract disease  
• Consider gastroenterology or hepatology consultations  
Once LFTs return  to normal, and depending on whether there is an explanation for the  LFT 
elevations, study drug dosing may resume,  after discussion with the Medical  Monitor  
Ref: FDA Guidance for Industry, titled: “Drug-Induced Liver Injury: Premarketing Clinical Evaluations”, issued 
July 2009  
4.6. Data Monitoring Committee  
A Data Monitoring Committee (DMC) will review pre -specified safety data (including AE and 
laboratory data) periodically in collaboration with the sponsor to ensure subject safety. A 
separate DMC charter will establish meeting frequency and scope of responsibilities.  DMC 
review wil l continue until the last meeting for the Phase 3 program is completed. 
Roxadustat  Protocol FGCL -4592 -059 Amendment 2  
FibroGen, Inc.  31 Confidential  
    5. ELIGIBILITY CRITERIA  
5.1. Inclusion Criteria  
1. Minimum age 18 years  
2. Subjects who have completed the treatment period of an ongoing roxadustat anemia study 
in the U.S. 
5.2. Exclusion Criteria  
1. Subje cts assigned to epoetin alfa in a previous ongoing roxadustat anemia study 
2. Pregnant or breastfeeding females  
3. Females of childbearing potential, unless using contraception as detailed in the protocol; male subjects with sexual partners of childbearing potential who are not on birth control unless the male subject agrees to use contraception 
4. Subjects who received roxadustat in a previous study that did not demonstrate adequate hemoglobin response per the investigator’s clinical judgment  
5. Any medical condition that in the opinion of the investigator may pose a safety risk to a subject in this study, or which may interfere with study participation 
Roxadustat  Protocol FGCL -4592 -059 Amendment 2  
FibroGen, Inc.  32 Confidential  
    6. STUDY DRUG/TREATMENT SUPPLY 
6.1. FibroGen Investigational Product  
6.1.1. Formulation  of roxadustat  
Roxadustat  is supplied by Fibr oGen, Inc. as an OSD of 20, 50, or 100 mg strength, made from 
active pharmaceutical ingredient and common USP/NF excipients and components. Complete 
traceability of the OSD will be documented in the CRF . 
6.1.2. Storage of Study Drug  
Roxadustat OSD should be protected from light, and stored at 15º to 30ºC (59º–86ºF) . 
All study -drug should also be stored in a securely locked area to which access is limited to 
appropriately qualified and authorized study personnel. 
6.1.3. Administration of Stud y Drug  
The study treatment OSD’s are to be swallowed whole with room -temperature drinking water . 
Study treatment (roxadustat) will be dispensed to subjects at each study visit with instructions for 
self-administration of the OSD on each dosing day, accordi ng to the dosing schedule.  
Study drug doses scheduled for a dosing frequency of TIW must be administered at least  2 days 
apart, and no more  than 4 days apart. Study drug doses scheduled for a dosing frequency of BIW 
must be administered at least 3 days apart, and no more  than 5 days  apart.  Study drug doses 
scheduled for a dosing frequency of QW must be administered at least 5 days apart, and no more  
than 9 days apart. 
See Section  4.3.2 for guidelines for dose adjustment to help maintain subjects’ Hb levels within a 
predefined target range.  
See Section  4.5.1 for guidelines on withholding and discontinuing dosing in response to changes 
in LFT values outside  of acceptable limits, and other hepatic abn ormalities.  
Roxadustat  Protocol FGCL -4592 -059 Amendment 2  
FibroGen, Inc.  33 Confidential  
    7. STUDY PROCEDURES  
7.1. Study Procedures by Visit  
An outline of the specific procedures and evaluations for each study visit is provided below. 
Refer to Appendix A  for the Schedule of Assessments and the Study Reference Manual for 
details.  
Although it would be ideal for study assessments to be performed precisely at specified dates, assessments will be allowed practical windows for completion.  
7.1.1. Treatment Period  
7.1.1.1. Baseline (Week 1)  
The following assessments will be performed prior to study drug administration. Assessments performed at the end -of-study visit in the previous roxadustat study may be used for those 
assessments noted below that need to be completed within 4 weeks prior to study drug administration.  
• Signed written informed consent within 4 weeks prior to study drug administration;  
• Inclusion criteria verification;  
• Exclusion criteria verification; 
• Vital signs: BP, heart rate (HR) and respirato ry rate;  
• Complete physical examination within 4 weeks prior to study drug administration;  
• Weight (use dry weight in HD subjects) within 4 weeks prior to study drug administration; 
• 12-lead ECG within 4 weeks prior to study drug administration;  
• Quality of Li fe questionnaire (FACT -An) within 4 weeks prior to study drug 
administration.  
• Laboratory tests:  
− CBC with white blood cell (WBC) differential and reticulocyte count;  
− Fasting serum chemistry (with LFTs, lipid profile, and glucose);  
− Human chorionic gonadotropin (hCG) test within 4 weeks prior to study drug administration (for women of childbearing potential only);  
− Serum iron studies:  iron, ferritin, transferrin (or total iron binding capacity 
[TIBC]), and TSAT;  
− Special laboratory tests (CHr, hepcidin, hs -CRP, plus select biomarkers) within 4 
weeks prior to study drug administration (only for subjects who had a baseline collected during prior roxadustat study);  
• Adverse events;  
Roxadustat  Protocol FGCL -4592 -059 Amendment 2  
FibroGen, Inc.  34 Confidential  
    • Concomitant medications; 
• Dispense roxadustat  (2-week supply for subject previously assigned to roxadustat and 
1 week supply for newly initiated to roxadustat with unstable Hb).  
7.1.1.1.1. Weekly Visits (±3 days) up to week 4 
• Weekly visits are only for the optional group of subjects newly initiated to roxadusta t 
and only need to be performed until Hb stabilizes. 
• Dispense weekly  roxadustat  
• Vital signs: BP, HR, and respiratory rate  
• Laboratory tests:  
− CBC with WBC differential and reticulocyte count  
• Adverse events  
• Concomitant medications  
7.1.1.1.2. Every 2 Week Visits (±3 days ) up to week 24  
• Dose Adjustments as needed  
• Dispense roxadustat  
• Vital signs: BP, HR, and respiratory rate  
• Laboratory tests:  
− CBC with WBC differential and reticulocyte count  
• Adverse events  
• Concomitant medications  
7.1.1.1.3. Every -4-Week Visit (±3 days)  
• Dose adjustment  as needed  
• Dispense roxadustat  
• Vital signs: BP, HR, and respiratory rate  
• Laboratory tests:  
− CBC with WBC differential and reticulocyte count  
− Fasting serum chemistry (with LFTs, lipid profile, and glucose)  
− Serum iron studies:  iron, ferritin, transferrin (or TIBC), and TSAT  
• Adverse events  
• Concomitant medications  
Roxadustat  Protocol FGCL -4592 -059 Amendment 2  
FibroGen, Inc.  35 Confidential  
    7.1.1.1.4. Every -12-Week Visits (±7 days)  
• Dose adjustment as needed  
• Dispense roxadustat  
• Vital signs: BP, HR, and respiratory rate  
• Physical examination  
• Weight (use dry weight in HD subjects)  
• Laboratory tests:  
− CBC with WBC differential and reticulocyte count  
− Fasting serum chemistry (with LFTs, lipid profile, and glucose)  
− Serum iron studies:  iron, ferritin, transferrin (or TIBC), and TSAT  
• Adverse events  
• Concomitant medications  
7.1.1.1.5. Every 24 Week Visits (±7 days ) 
• Dose adjustment as needed  
• Dispense roxadustat  
• Vital signs: BP, HR, and respiratory rate  
• 12-lead ECG  
• Physical examination  
• Weight (use dry weight in HD subjects)  
• Laboratory tests:  
− CBC with WBC differential and reticulocyte count  
− Fasting serum chemistry (with LFTs lipid profile, and glucose)  
− Serum iron studies:  iron, ferritin, transferrin (or TIBC), and TSAT  
− Special labs (CHr, hepcidin, hs -CRP, plus select biomarkers) (only for subjects 
who had a baseline collected during prior roxadustat study)  
• Quality of L ife questionnaire (FACT -An) 
• Adverse events  
• Concomitant medications  
7.1.1.1.6. Termination / Early Termination (ET) Visit  
This visit is to occur 4 weeks after final dose. If a subject discontinues from the study during the 
treatment period, perform the ET assessments at the time of withdrawal from dosing:  
Roxadustat  Protocol FGCL -4592 -059 Amendment 2  
FibroGen, Inc.  36 Confidential  
    • Physical examination  
• Weight (use dry weight in HD subjects)  
• Vital signs: BP, HR, and respiratory rate  
• 12-lead ECG  
• Laboratory tests:  
− CBC with WBC differential and reticulocyte count  
− Fasting serum chemistry (with LFTs, lipid profile, and glucose)  
− hCG test for women of childbearing potential only 
− Serum iron studies:  iron, ferritin, transferrin (or TIBC), and TSAT  
− Special labs (CHr, hepcidin, hs -CRP, plus select biomarkers) (only for subjects 
who had a baseline  collected during prior  roxadustat study)  
• Quality of Life questionnaire (FACT -An) 
• Adverse events  
• Concomitant medications  
7.2. Post-Treatment Follow -Up Period  
The Follow -up Period begins on the week after the last dose of study treatment, and continues 
for 4 we eks. 
7.3. Missed Visits 
Every attempt should be made to complete all study visits as outlined in the Schedule of Study 
Assessments ( Appendix A). All missed study visits will be considered protocol deviations. 
7.4. Unscheduled Visits  
Unscheduled visit(s) and laboratory assessments may be required at the discretion of the investigator. Ple ase refer to the CRF Completion Guidelines located in the Study Reference 
Manual for additional information. 
7.5. Assessments 
Central laboratory data should be reviewed as soon as they are received.  Subject management is 
dependent upon close review of the labor atory data.  Vital signs should be recorded in a quiet 
room. 7.5.1. Central Laboratory  
All laboratory tests of blood specimens will be performed by a central laboratory. A Central 
Laboratory Manual with instructions on specimen collection, processing, storing, and shipping to the central laboratory will be provided to all participating sites.  
Roxadustat  Protocol FGCL -4592 -059 Amendment 2  
FibroGen, Inc.  37 Confidential  
    Serum chemistry, iron studies, serum pregnancy tests, and CBC with white cell differential and 
reticulocyte counts will be performed and analyzed by a central laboratory during the treatment and post -treatment Follow -up Periods. Fasting is preferred for serum chemistry, if possible. 
The central laboratory will also be able to perform unscheduled testing (e.g., to confirm abnormal LFTs or to obtain an additional Hb value). Acute clinical management may dictate the 
need for the services of a local laboratory.  
Required scheduled laboratory tests are to be performed by a central laboratory unless otherwise specified.  Laboratory parameters to be measured in this study are as follows:  
• (Fasting) Serum Chemistry  
Fasting is preferred for serum chemistry, if possible. Serum chemistry in this study will consist of the following laboratory analytes:  
• Sodium  
• Potassium  
• Chloride  
• Calcium  
• Magnesium  
• Bicarbonate  
• Phosphorus  
• Creatinine  
• Glucose  
• Uric Acid  
• Albumin  
• Total protein  
• Lactate dehydrogenase  • Lipid Profile  
− Total Cholesterol  
− LDL  
− HDL  
− Triglyceride  
• LFTs:  
− ALT  
− AST  
− Bilirubin (total and 
direct)  
− GGT  
− ALP  
Abbreviations:  ALP = alkaline phosphatase; ALT  = alanine aminotransferase; 
AST = aspartate aminotransferase; GGT  = gamma- glutamyl transferase; HDL  = high-density 
lipoprot ein; LDL = low density lipoprot ein; LFT  = liver function test;  
The LFTs and Lipid Profile are subse ts of the serum chemistry panel.  
Roxadustat  Protocol FGCL -4592 -059 Amendment 2  
FibroGen, Inc.  38 Confidential  
    • Complete Blood Count  
Complete blood count will consist of the following laboratory analytes:  
• Hb 
• Hematocrit  
• RBC  
• Mean corpuscular volume  
• Mean corpuscular Hb  
• Mean corpuscular Hb 
concentration  
• WBC  • Neutrophils  
• Banded neutrophils  
• Lymphocytes  
• Monocytes  
• Eosinophils  
• Basophils  
• Platelet count  
• Reticulocyte count  
Abbreviations:  Hb = hemoglobin ; RBC  = red blood cell ; WBC  = white blood cell.  
• Coagulation Parameters  
The central laboratory may be requested to draw PT and calculate an INR in subjects whose LFT results trigger the HMP (see Section  1.1).  
• Serum Iron Studies:  iron, ferritin, transferrin (or TIBC), and TSAT.  
• Serum Pregnancy Test.  
• Special Laboratory Analytes:  CHr, hepcidin, and hs -CRP.  
• Select Biomarkers : A set of serum samples will be drawn and stored for the future 
analysis of relevant select biomarkers.  
7.5.2. Local Laboratory 
No local laboratories will be used for regular, standard- laboratory testing during the study. 
7.5.3. Vital Signs  
Subjects should take their study medication after the vital sign measures and not immediately before.  For subjects on HD, BP should be taken prior to and after the dialysis procedure. For 
subjects on PD, BP should be taken during study visit.  
7.5.4. Electrocardiogram  
Twelve- lead ECGs will be performed on all subjects for safety assessments at Baseline (may use 
end of  study visit of previous  roxadustat study if it is within 4 weeks prior to study drug 
administration), Termination/ ET visit.  Triplicate ECGs are not required.  
7.5.5. Quality of Life Questionnaire  
All study subjects will be asked to complete Quality of Life questionnaire (FACT -An) at 
Baseline (may use end of study visit of previous roxadustat study if it is within 4 weeks prior to study drug administration), and Termination/ ET Visit.  
Roxadustat  Protocol FGCL -4592 -059 Amendment 2  
FibroGen, Inc.  39 Confidential  
    8. SUBJECT DISCONTINUATION 
Subjects may withdraw from the study at any time. Withdr awn subjects should be strongly 
advised to complete the 4 -week Follow -up Period procedures as outlined in the Schedule of 
Study Assessments in Appendix A . The appropriate documentation must be entered on the Study 
Termination CRF. Subjects should be discontinued from the study for any of the following 
reasons:  
• Significant noncompliance with study procedures, as determined by principal 
investigator and study medical monitor;  
• Subject no longer consents to participate in the study;  
• Physician decision that it is in the best interest of the subject to be withdrawn from the study;  
• Need for ESA rescue therapy due to lack of efficacy and/or lack of tolerability to 
roxadustat;  
• Study medical monitor and principal investigator agree that a s ubject’s intercurrent 
illness is significantly interfering with study assessments; 
• The study is terminated by FibroGen for any reason or by the DMC due to safety 
concerns;  
• Subject is lost to follow -up for the duration of the study;  
• At FibroGen’s discretio n; 
• Subject is found to be pregnant;  
• Death.  
Subjects who withdraw from the study will be followed for AEs as described in Section  11 of 
this protocol. The reason for withdrawal from the study will be documented in the CRFs. 
Women of childbearing potential who withdraw from this study will continue contraception for 
at least 12 weeks following the last roxadustat administration. Male subjects with partne rs of 
childbearing potential must agree to use a medically acceptable method of contraception during the trial and for at least 12 weeks following the last roxadustat administration.  
Roxadustat  Protocol FGCL -4592 -059 Amendment 2  
FibroGen, Inc.  40 Confidential  
    9. STUDY TERMINATION BY FIBROGEN  
FibroGen has the right to terminate this study at any time. 
Roxadustat  Protocol FGCL -4592 -059 Amendment 2  
FibroGen, Inc.  41 Confidential  
    10. STATISTICS  
10.1. Sample Size Determination  
This is an open- label, long- term maintenance study of roxadustat anemia therapy in dialysis and 
non-dialysis CKD subjects who have completed the treatment period of an roxadustat anemia 
study in the U.S .  
Power analysis not used to determine the sample size.  
10.2. Treatment Assignment  
Subjects assigned to roxadustat in the previous study will receive the same study treatment 
assignment. 
An optional treatment group allows subjects who received placebo or blind ed study drug to start 
treatment with roxadustat.  
Data will be summarized using the following subject populations as deemed appropriate  
• Dialysis Group: Subjects on dialysis previously treated with roxadustat at the time of 
entry to study 
• Non-Dialysis Group: CKD subjects previously treated with roxadustat not on dialysis 
at the time of entry to study  
• Newly Initiated Group: Subjects who were not previously treated with roxadustat at study entry that have to be corrected  
The roxadustat (OSD) will be supplied i n an open- label manner to all subjects.  
10.3. Analysis Population  
The Safety population, defined as all subjects who have received any dose of study treatment, will be included in the safety analyses.  
The Efficacy Evaluable (EE) population is defined as all subj ects who receive any dose of study 
treatment and have non -missing Hb measurement at Baseline and at least one non -missing post -
baseline Hb measurement.  
10.4. Interim Analysis  
The study will have no formal interim analysis with statistical inference. Safety and efficacy will be monitored on an ongoing basis. 
A DMC will review pre -specified safety data (including AE and laboratory data) periodically in 
collaboration with the sponsor to ensure subject safety. A separate DMC charter will establish 
meeting frequency and scope of responsibilities. DMC review will continue until the last meeting for the Phase 3 program is completed. 
10.4.1. Subject Enrollment and Disposition  
A table will provide the number of enrolled subjects, Safety subjects, EE subjects, and subjects 
who terminated the treatment period/study early along with the reason for ET. 
Roxadustat  Protocol FGCL -4592 -059 Amendment 2  
FibroGen, Inc.  42 Confidential  
    10.5. Replacement of Subjects  
No replacement is planned for subjects who drop out prematurely.  
10.6. Statistical Analysis  
Summary statistics will consist of number of subjects (N), means, stand ard deviations, medians, 
and minimum (min) and maximum (max) values for continuous variables, and counts and 
percentages for categorical variables. A last -observation- carried -forward (LOCF) method may be 
used to impute any missing Hb values. For efficacy e ndpoints, the standard error and 95% 
confidence intervals will be added as part of the descriptive summaries. Tables will summarize 
all efficacy and safety measures by Dialysis, Non Dialysis, and Newly Initiated group and time point, as appropriate.  
10.6.1. Demogr aphics and Baseline Characteristics  
Demographics (age, race, sex), baseline characteristics (e.g., height, weight), and subject disease characteristics will be summarized for all enrolled subjects.  
Descriptive statistics will be calculated for continuous v ariables (age and weight) and frequency 
counts and percentages will be tabulated for categorical variables (e.g., gender, race, and body mass index).  
10.6.2. Efficacy Analyses  
Hemoglobin results obtained from the central laboratory will be used for all efficacy an alyses.  
Baseline Hb value for efficacy analysis is defined as the mean of the central laboratory Hb value from the Baseline Visit Day 1 (prior to receiving the first dose of study drug in this study), plus 
any other central laboratory Hb values obtained wi thin 15 days prior to Day 1. Baseline eGFR, 
ferritin, TSAT, and other efficacy endpoints are defined as the last value prior to the first dose of study treatment.  
All efficacy analyses will be based on the EE population. 
• Monthly mean Hb values and changes from baseline will be summarized descriptively for the Dialysis, Non- Dialysis , and Newly Initiated populations at each 
scheduled time point as well as monthly  
• The number (%) of subjects maintaining Hb ≥10 g/dL during study participation, the composite rat e of summarized rescue therapy events (transfusions, IV iron, ESAs) 
and rate of individual rescue therapy events, and the number (%) of subjects receiving phlebotomies will be summarized for the Dialysis, Non Dialysis and Newly Initiated 
populations  
• The dose level at the time of Hb response will be summarized descriptively  
• The frequency of dose increases and decreases and use of rescue therapy will also be tabulated. Median time to Hb response will be estimated for each subject previously receiving placebo (Newly Initiated group) using the Kaplan- Meier method. 
Hemoglobin response is defined as a Hb increase from baseline of at least 1.0 g/dL. In addition, median initial responsive time and dose will be tabulated to evaluate when an initial Hb change from bas eline reaches at least 1.0 g/dL. Number (%) of 
Roxadustat  Protocol FGCL -4592 -059 Amendment 2  
FibroGen, Inc.  43 Confidential  
    subjects, scheduled Hb values, and consecutive Hb values achieved for a variety of 
Hb ranges between 11.0 and 13.0 g/dL, as well as above or below these ranges, during 4- week study intervals throughout the tre atment period will be tabulated.  
10.6.3. Exploratory Analyses  
Quality of life composite scores, as well as selected subscale scores will be compared to baseline 
values and between treatment assignments.  
Descriptive statistics will be generated for exploratory endp oints and biomarkers. Correlations 
between parameters will be explored.  
10.6.4. Safety Analyses  
All subjects who received any dose of roxadustat will be included in the safety analyses.  
All safety assessment data, including laboratory assessments, vital signs, physical examinations, 
ECGs, AEs, and concomitant medications and therapies, will be summarized by time point of 
collection as appropriate for the Dialysis, Non- Dialysis, and Newly Initiated populations. 
An AE data listing by subject, including verbatim term, preferred term, study treatment, severity, and relationship to study treatment, will be presented. 
The number (%) of subjects experiencing treatment -emergent AEs will be summarized using 
frequency counts for the Dialysis, Non- Dialysis, and newly initiated populations.  
Descriptive statistics will be calculated for quantitative safety data and frequency counts will be 
compiled for classification of qualitative safety data. Laboratory data will be summarized for each time point that specimens are col lected. Change- from -baseline values may be calculated for 
selected laboratory parameters (baseline refers to blood drawn prior to the first study treatment). 
Laboratory values outside of normal limits will be identified in the subject data listings with flags for high and low values. Laboratory results obtained from the central laboratory will be 
used for all safety analyses.  
ECG results will be classified using frequency counts for normal, clinically insignificant abnormalities, and clinically significant abnormalities by time point of collection. Descriptive statistics will be calculated for QT intervals.  
Blood pressure, HR, and respiratory rate data will be summarized descriptively by various time intervals both as absolute values and as changes from base line. 
A summary table and/or listing will present all abnormal physical examination results throughout the study. 
10.7. Statistical Analysis Plan  
A detailed Statistical Analysis Plan (SAP) will be finalized prior to data analysis. Any significant 
changes to the analyses described in this protocol will be highlighted in the SAP. Deviations in analyses from the SAP will be detailed in the clinical study report.  
Roxadustat  Protocol FGCL -4592 -059 Amendment 2  
FibroGen, Inc.  44 Confidential  
    11. SAFETY  
11.1. Background  
Adverse event reports from investigators are the critical building blocks to the developing safety 
profile of the study drug. Therefore, with the exception of study endpoints, the investigator must 
immediately report to the sponsor all SAEs, regardless of whether the investigator believes they 
are drug related.  Additionally, the investigator  must record nonserious AEs at regular intervals 
during the course of the study. 
The definitions of an AE, suspected adverse reaction, adverse reaction, and SAE are described 
below in accordance with the Food and Drug Administration (FDA) Final Rule Vol 75, No 188, September 29, 2010 and the International Conference on Harmonization (ICH) E2A guidance.  
11.2. Definitions  
11.2.1. Definition of an Adverse Event  
An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered dr ug related. 
An AE can be any unfavorable and unintended sign (e.g., an abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, without any judgment about causality.  An AE can arise from any use of the drug (e.g., off -label use, use in combination with 
another drug) and from any route of administration, formulation, or dose, including an overdose.  
Out-of-range Hb values need not be reported as AEs as these Hb values will be captured and 
analyzed in the efficacy analyses.  
An AE includes medical conditions, signs, and symptoms not previously observed in the subject that emerge during the protocol -specified AE reporting period, including signs or symptoms 
associated with an underlying condition that were not present prior to the AE reporting period (see Section  11.3.1).  
11.2.2. Definition of an Adverse Reaction  
An adverse reaction means any AE caused by a drug. 
11.2.3. Definition of a Suspected Adverse Reaction  
A suspected adverse reaction means any AE for which there is a reasonable possibility that the 
drug caused the AE. The term, “reasonable possibility” means that there is evidence to suggest a causal relationship b etween the drug and the AE. A suspected adverse reaction implies a lesser 
degree of certainty about causality than the term, “adverse reaction.”  
Roxadustat  Protocol FGCL -4592 -059 Amendment 2  
FibroGen, Inc.  45 Confidential  
    11.2.4. Definition of a Serious Adverse Event  
An SAE is an AE that results in any of the following outcomes:  
• Death;  
• A life-threatening AE (i.e., if in the view of the investigator or sponsor, the subject 
was at immediate risk of death at the time of the event.  Life -threatening does not 
include an event that, had it occurred in a more severe form, might have caused 
death) ; 
• Inpatient hospitalization or prolongation of existing hospitalization;  
• A persistent or significant incapacity or substantial disruption of the ability to conduct 
normal life functions;  
• A congenital anomaly or birth defect; or  
• Is an important medical even t (based on appropriate medical judgment, the event 
jeopardizes the subject and may require medical or surgical intervention to prevent 
one of the above -listed outcomes).  
11.3. Procedures for Eliciting, Recording, and Reporting Adverse Events  
11.3.1. Adverse Event Reporting Period  
The study period during which all AEs and SAEs must be reported begins after informed consent is obtained and ends 28 days after the last treatment. 
Adverse events will be followed until resolved, stable, or until the subject’s last study visit . If an 
AE is not resolved or stabilized at the subject’s last visit, it is up to the discretion of the 
investigator and study medical monitor to determine if further monitoring of the event is warranted.  
Adverse events collected prior to dosing of study drug will be considered “treatment non-emergent” while those reported after the first dose of study drug will be considered “treatment emergent” and be assessed for relationship to study drug. 
During the AE reporting period, study site personnel will query each subject at each visit to 
actively solicit any AE occurring since the previous visit. This does not preclude the site from collecting and recording any AEs reported by the subject to site personnel at any other time.  
11.3.2. Assessing Adverse Event Severity  
The investigator should use the National Cancer Institute Common Terminology Criteria for 
Adverse Events (NCI CTCAE v4.0), which may be found at:  
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40 
This will serve as guidance fo r specific severity assessment criteria.  
The NCI CTCAE provides a descriptive terminology used for AE reporting and severity grading. 
It is a comprehensive dictionary of medical terms that facilitates accurate and consistent medical coding. It does not contain every event that may occur in a given study. Adverse events that are not covered by the NCI -specific criteria will be assessed for severity  using the following criteria:  
Roxadustat  Protocol FGCL -4592 -059 Amendment 2  
FibroGen, Inc.  46 Confidential  
    • Grade 1:  Mild; asymptomatic or mild symptoms; clinical or diagnostic observations  
only; intervention not indicated.  
• Grade 2:  Moderate; minimal, local or noninvasive intervention indicated; limiting 
age-appropriate instrumental activities of daily living (e.g., preparing meals, shopping 
for groceries or clothes, using the telephone, man aging money).  
• Grade 3:  Severe or medically significant but not immediately life threatening; 
hospitalization or prolongation of hospitalization indicated; disabling; limiting self -
care activities of daily living (e.g., bathing, dressing and undressing, fee ding self, 
using the toilet, taking medications, and not bedridden).  
• Grade 4:  Life -threatening consequences; urgent intervention indicated.  
• Grade 5:  Death related to AE.  
11.3.3. Assessing Relationship of Adverse Event to Study Drug  
Most of the information about the safety of a drug prior to marketing comes from clinical trials; 
therefore, AE reports from investigators are critically important.  Moreover, appropriately 
deciding whether the AE meets the definition of a suspected adverse reaction is usually the most difficult determination, but it is critical to avoid the miscategorization o f the product’s safety 
profile.  
Due to the historical tendency for assessment of relationship to default as possibly related, the FDA has issued new guidance that clarifies the inten t of the phrase “reasonable possibility” in 
the definition of “associated with the use of the drug.”  Default reporting of individual events as 
“possibly related” is uninformative and does not meaningfully contribute to the development  of 
the product safety profile.  
The investigator must provide an assessment of the relationship of the AE to study drug in accordance with the guidance below. Absence of an alternative cause would not normally be considered enough evidence to assess an event as “possibly relat ed” or “related” to study drug.  
Related (Adverse Reaction):  
• Any event for which there is evidence to conclude that the study drug caused the event.  
Possibly Related (Suspected Adver se Reaction):  
• A single occurrence of an event that is uncommon and known to be strongly associated with drug exposure, such as angioedema, anaphylaxis during infusion, rhabdomyolysis, Stevens -Johnson syndrome, etc.  
• One or more occurrences of an event that is not commonly associated with drug exposure but is otherwise uncommon in the population exposed to the drug, such as tendon rupture.  
Not Related:  
• The event represents the underlying disease (e.g., disease -related symptoms, disease 
progression)  
Roxadustat  Protocol FGCL -4592 -059 Amendment 2  
FibroGen, Inc.  47 Confidential  
    • The event represents a comorbid condition present at the time the subject ent ered the 
study 
• The event represents a known adverse reaction associated with a co -medication 
received by the study subject  
• The event is common for the study population (e.g. cardiovascular events in an 
elderly population)  
• The event has no plausible relationship to study drug 
• The event is a study endpoint (e.g., mortality, major morbidity)  
The investigator must provide an assessment of the relationship of the event to study drug, as this information is very important to monitor the real -time safety of the st udy drug. However, as the 
manufacturer of the study drug, FibroGen is responsible for making the final causality assessment for individual reports, and for reporting suspected adverse reactions and adverse reactions to Health Authorities.  
In order to support this practice, FibroGen will perform periodic aggregate data reviews to assess for: 1) one or more occurrences of rare/uncommon AEs, and; 2) increases in the observed frequencies of AEs that would be expected for the underlying disease and study populat ion. 
While the investigator must provide an assessment of the relationship of the event to study drug, in most cases only aggregate data review will be used to make the determination of the relationship of the study drug to a given AE. This information will be updated periodically and provided in the IB. 
11.3.4. Reporting Serious Adverse Events on the SAE Report Form  
All SAEs must be reported to FibroGen immediately.  
To report an SAE, the investigator must e -mail or fax an SAE Report Form to FibroGen within 
24 hour s of becoming aware of the event. Follow -up reports must be submitted in a timely 
fashion as additional information become s available.  
For each SAE observed, the investigator should obtain all of the information available about the 
event, including (but not limited to): hospital discharge diagnoses, hospital discharge note, death certificate, appropriate laboratory findings (including autopsies and biopsy results), and clinical examinations (including radiological examinations and clinical consultations). 
11.3.4.1. Reporting Serious Adverse Events to the Institutional Review Board/Ethics 
Committee  
The investigator is responsible for notifying his/her Institutional Review Board (IRB) or 
Independent Ethics Committee (IEC) of SAEs in accordance with local regulations. Fi broGen, or 
its safety representative, will provide to the investigator a copy of any expedited safety reports that it intends to file with a regulatory authority.  
11.3.4.2. Deaths  
For any death occurring during the subject’s study participation, regardless of attribution, the investigator will report the death immediately to the study medical monitor.  
Roxadustat  Protocol FGCL -4592 -059 Amendment 2  
FibroGen, Inc.  48 Confidential  
    The investigator should notify FibroGen of any death or other SAE occurring after a subject has 
discontinued or terminated study participation that may reasonably be re lated to the study. 
The investigator must submit the SAE Report Form and complete the appropriate CRF page for the event that led to the subject’s death. This includes death attributed to progression of anemia or CKD.  
When reporting a death, the event or c ondition that caused or contributed to the fatal outcome 
should be recorded as the primary event term on the SAE Report Form.  
11.3.5. Pregnancies:  Reporting and Follow -up of Subjects  
A pregnancy in a female subject or a male subject’s female partner must be confirmed by a 
positive serum beta -hCG test.  If a female subject or the female partner of a male subject becomes 
pregnant while the subject is receiving study treatment or within 3 months after the last dose of study treatment, a Pregnancy Report Form must  be completed and submitted to FibroGen within 
24 hours of the investigator learning of the pregnancy. A pregnant subject is immediately withdrawn from receiving study treatment. The investigator must follow the pregnancy to completion to ascertain both its outc ome and whether any AEs occur.  
Pregnancy itself is not an AE. Abortion, whether accidental, therapeutic, or spontaneous, should always be classified as serious, recorded on an SAE Report Form, and reported to FibroGen within 24 hours of the investigator learning of the event. Similarly, any medically significant congenital anomaly/birth defect in a child born to a female subject or the female partner of a male subject exposed to the investigational product should be recorded and reported as an SAE.  
The outcome of the pregnancy must be reported by the investigator on a  Pregnancy Outcome 
Report Form, which should be sent to FibroGen within 24 hours of the investigator learning of 
the outcome.  
11.3.6. Abnormal Laboratory Findings  
Laboratory values will be collected throughout the study to assess for safety. The investigator must review and assess all laboratory results in a timely manner and must report abnormal laboratory findings if they are clinically significant or if there are  associated signs and 
symptoms.  
An abnormal laboratory finding in absence of any other signs or sympt oms is not necessarily an 
AE/SAE.  If the abnormal laboratory finding is accompanied by signs or symptoms, report the 
signs and symptoms as the AE/SAE in lieu of the abnormal laboratory value. If a diagnosis is available, report the diagnosis. 
Clinically significant laboratory abnormalities that reflect a change from the initial screening 
value and that require active management may be considered AEs (e.g., abnormalities that require study treatment dose modification, discontinuation, more frequent follow -up 
assessments, etc.).  However, out -of-range Hb values should not be reported as AEs as these Hb 
values will be captured and analyzed in the efficacy analyses.  
Roxadustat  Protocol FGCL -4592 -059 Amendment 2  
FibroGen, Inc.  49 Confidential  
    12. STUDY MONITORING  
FibroGen or its designee will perform periodic monitoring visits and site closeout visits 
following the site prequalification and/or initiation of the study site. The investigator must provide direct access to, and allocate sufficient space and time for, the monitor to inspect subject source records, CRFs, queries, collection of local laboratory normal ranges (if applicable), 
investigational product accountability records, and regulatory documents in accordance with 
GCP and the ICH E6 guideline. 
The purpose of trial monitoring is to verify the following:  
• The rights and well -being of hum an subjects are protected;  
• The reported data are accurate, complete, and verifiable from source documents;  
• All data are collected, tracked, and submitted by the site to FibroGen or its designee, 
including unscheduled and missed assessments;  
• The reported da ta are reconciled across all data sources (e.g., laboratory, safety, 
clinical databases);  
• The conduct of the trial complies with the currently approved protocol/amendment(s), 
with GCP, and with the applicable regulatory requirement(s).  
The investigator mus t also permit the US FDA or other applicable regulatory authorities to 
inspect facilities and records pertaining to this study if so requested. The investigator must notify 
FibroGen immediately if he is notified of an inspection pertaining to this study by the U.S. FDA or other applicable regulatory authorities.  
12.1. Data Quality Assurance  
The following steps will be taken to ensure that the study is conducted by the study site in compliance with the study protocol, GCP, and other applicable regulatory requireme nts. 
• Investigator meeting and/or investigator site initiation; 
• Routine study site monitoring;  
• Documented study and system training;  
• CRF and query review against source documents;  
• Collection of local laboratory normal ranges, if applicable.  
12.2. Compliance with Laws and Regulations  
This study will be conducted in accordance with the US FDA regulations, the ICH E6 Guideline for GCP, the Declaration of Helsinki, and applicable local, state, and federal laws, as well as other applicable country laws. 
Roxadustat  Protocol FGCL -4592 -059 Amendment 2  
FibroGen, Inc.  50 Confidential  
    12.3. Data Collection  and Handling  
Source Documents  
Source records are original documents, data, and records that are relevant to the clinical trial. The 
investigator will prepare and maintain adequate and accurate source documents. These documents are designed to record all observations and other pertinent data for each subject 
enrolled in this clinical trial. Source records must be adequate to reconstruct all data transcribed onto the CRFs and resolved queries.  
Data Collection, Handling, and Verification  
Authorized site personnel will enter all required data onto paper or electronic CRFs. Data may be entered into a validated, clinical database compliant with 21 Code of Federal Regulations (CFR) Part 11 regulations. The database will be a secured, password- protected system  with full audit 
trail. 
FibroGen and/or its designee will review all subject data. Data that appear inconsistent, incomplete, or inaccurate will be queried for site clarification.  
Adverse events and concomitant medications will be coded using industry standard dictionaries (e.g., Medical Dictionary for Regulatory Activities [MedDRA] and World Health Organization drug dictionaries).  
The investigator is responsible for reviewing, verifying, and approving all subject data, i.e., CRFs and queries prior to study completion. 
Quality Compliance  
A database audit may be conducted to ensure data quality and integrity. 
Roxadustat  Protocol FGCL -4592 -059 Amendment 2  
FibroGen, Inc.  51 Confidential  
    13. HUMAN SUBJECTS  
13.1. Ethical Considerations  
The study will be conducted in accordance with US FDA regulations, the ICH E6 Guideline for 
GCP, the Declaration o f Helsinki, any other applicable regulatory requirements, and IRB or IEC 
requirements.  
13.2. Communication with the Institutional Review Board or Independent Ethics Committee  
This protocol, the informed consent form (ICF), the IB, and any information to be given to the subject must be submitted to a properly constituted IRB/IEC by the investigator for review; these have to be approved by the IRB/IEC before the study is initiated and before any investigational 
product is shipped to the investigator. In addition, a ny subject recruitment materials must be 
approved by the IRB/IEC before the material is presented to the subject. 
The investigator is responsible for obtaining reapproval by the IRB/IEC annually or more 
frequently in accordance with the regulatory requirem ents and policies and procedures 
established by the IRB/IEC. Copies of the investigator’s annual report and other required report to the IRB/IEC and copies of the IRB/IEC continuance of approval must be furnished to FibroGen. A copy of the signed form FDA 1572 must also accompany the above approval letter provided to FibroGen.  
Investigators are also responsible for promptly informing the IRB/IEC of any protocol changes or amendments, changes to the IB, and other safety- related communications from FibroGen. 
Written documentation of IRB/IEC approval must be received before the amendment is implemented.  
Investigators must also enter the names of the staff that are involved in the study on the Delegation of the Authority form and sign the form (including their r esponsibilities). This form 
must be updated when responsibilities of the staff change.  
13.3. Informed Consent Form  
No study procedure may be implemented prior to obtaining a signed, written ICF from the subject or the subject’s legally authorized representative.  IRB/IEC review and approval are 
required for the ICF. The final IRB/IEC approved ICF must be provided to FibroGen for regulatory purposes.  
If there are any changes to the ICF during the subject’s participation in the study, the revised ICF must receive th e written approval of the IRB/IEC before use; current subjects must be re -
consented to the revised version of the ICF.  
13.4. Subject Confidentiality  
Release of research results should preserve the privacy of medical information and must be carried out in accordance with Department of Health and Human Services Standards for Privacy of Individually Identifiable Health information, 45 CFR Parts 160 and 164, and Health Insurance Portability and Accountability Act (HIPAA), if applicable.  
Roxadustat  Protocol FGCL -4592 -059 Amendment 2  
FibroGen, Inc.  52 Confidential  
    Subject medical information obtained as part of this study is confidential and may only be 
disclosed to third parties as permitted by the Informed Consent and HIPAA Authorization Form or separate authorization to use and disclose personal health information signed by the subject, or unless permitted or required by law. The subject may request in writing that medical information be given to his/her personal physician. 
Roxadustat  Protocol FGCL -4592 -059 Amendment 2  
FibroGen, Inc.  53 Confidential  
    14. INVESTIGATOR REQUIREMENTS  
The investigator must be medically qualified to directly supervise the conduct of the trial at his 
or her site.  The investigator will permit trial- related monitoring, audits, IRB/IEC review, and 
regulatory inspection(s), providing direct access to source data/documents.  
14.1. Study Medication Accountability  
All study drug required for completion of this s tudy will be provided by FibroGen. The recipient 
will acknowledge receipt of the drug by returning the appropriate documentation form indicating shipment content and condition. Damaged supplies will be replaced.  
The roxadustat  investigational product, including partial and empty bottles, must be maintained 
at the study site until FibroGen or its designee verifies drug accountability and provides 
instruction for the return of the investigational product to FibroGen’s drug distri bution depot.  
Accurate records of all study drug received, dispensed, returned, and disposed of by the study 
site according to the Study Reference Manual should be recorded using the Drug Inventory Log.  
14.2. Disclosure of Data  
Data records generated by this stu dy must be available for inspection upon request by 
representatives of the FDA or other regulatory agencies, national and local health authorities, FibroGen monitors/representatives and collaborators, auditors, and the IRB/IEC for each study site. 
The Prin cipal Investigator or sub- investigator should promptly notify FibroGen of any audits 
scheduled by any regulatory authorities and promptly forward copies of any audit reports received to the sponsor.  
14.3. Retention of Records  
The investigator shall retain record s required to be maintained under 21 CFR 312.62(c) for a 
period of 2 years following the date a marketing application is approved for the drug for the indication for which it is being investigated. If no application is to be filed or if the application is 
not approved for such indication, the investigator shall retain these records until 2 years after the investigation is discontinued and the FDA is notified. 
If the investigator moves or retires, he or she should identify in writing, the designee who will be 
responsible for record keeping. Archived data may be retained on electronic records or similar medium if a back -up exists and a hard copy is obtainable if required. No records will be 
destroyed without the prior written consent of FibroGen.  
Roxadustat  Protocol FGCL -4592 -059 Amendment 2  
FibroGen, Inc.  54 Confidential  
    15. PUBLICATION P OLICY  
A detailed explanation of FibroGen’s publication policy is described in the Clinical Trial 
Agreement.  
Roxadustat  Protocol FGCL -4592 -059 Amendment 2  
FibroGen, Inc.  55 Confidential  
    16. REFERENCES  
Besarab A, Bolton WK, Browne JK, et al. (1998) The effects of normal as compared with low 
hematocrit values in patients with cardiac dise ase who are receiving hemodialysis and epoetin. N 
Engl J Med 339: (9):584- 590 
Buchler P, Reber HA, Buchler M, et al. (2003) Hypoxia -inducible factor 1 regulates vascular 
endothelial growth factor expression in human pancreatic cancer. Pancreas 26: (1):56- 64 
Coresh J, Selvin E, Stevens LA, et al. (2007) Prevalence of chronic kidney disease in the United States. JAMA 298: (17):2038- 2047 
Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW (1987) Correction of the anemia of end -stage renal disease with recombinant human erythropoietin. Results of a 
combined phase I and II clinical trial. N Engl J Med 316: (2):73- 78 
Eschbach JW, Kelly MR, Haley NR, Abels RI, Adamson JW (1989) Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med 321: (3):158-163 
Fan C, Iacobas DA, Zhou D, et al. (2005) Gene expression and phenotypic characterization of 
mouse heart after chronic constant or intermittent hypoxia. Physiol Genomics 22: (3):292- 307 
Frohna, P., Milwee, S., Pinkett, J, Lee, T., Moore -Perry, K, Chou, J., and Ellison, RH (2007) 
Preliminary Results from a Randomized, Single -Blind, Placebo- Controlled Trial of 
ROXADUSTAT, a Novel Hypoxia Inducible Factor Prolyl Hydroxylase Inhibitor, in Subjects with CKD Anemia (Abstract #SU -PO806). Abstract:  J Am Soc Nephrol 18 763A  
Gray MJ, Zhang J, Ellis LM, et al. (2005) HIF -1alpha, STAT3, CBP/p300 and Ref -1/APE are 
components of a transcriptional complex that regulates Src -dependent hypoxia -induced 
expression of VEGF in pancreatic and prostate carcinomas. Oncogene 24: (19):3110- 3119 
Greijer A, van der GP, Kemming D, et al. (2005) Up- regulation of gene expression by hypoxia is 
mediated predominantly by hypoxia -inducible factor 1 (HIF -1). J Pathol 206: (3):291- 304 
Hu CJ, Wang LY, Chodosh LA, Keith B, Simon MC (2003) Differential roles of hypoxia -
inducible factor 1alpha (HIF -1alpha) and HIF -2alpha in hypoxic gene regulation. Mol Cell Biol 
23: (24):9361- 9374  
Kausz AT, Levey AS (2002) The care of patients with chronic kidney disease. J Gen I ntern Med 
17: (8):658- 662 
NKF K/DOQI (2007) KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: update of hemoglobin target. Am J Kidney Dis 50: (3):471- 530 
Remuzzi G, Minetti L. (2000)  Hematologic Consequences of Renal Failure.  The Kidney. 6th ed. 
Pages 2079- 2087.  
Schwartz AB, Prasad V, Garcha J (2004) Anemia of Chronic Kidney Disease: A Combined Effect of Marginal Iron Stores and Erythropoietin Deficiency. Dialysis and Transplantation 33: (12):758- 768 
Scortegagna M, Ding K, Zhang Q, et al. (2005) HIF -2alpha regulates murine hematopoietic 
development in an erythropoietin- dependent manner. Blood 105: (8):3133- 3140 
Roxadustat  Protocol FGCL -4592 -059 Amendment 2  
FibroGen, Inc.  56 Confidential  
    Semenza GL (1998) Hypoxia -inducible factor 1: master regulator of O2 homeostasis. Curr O pin 
Genet Dev 8: (5):588- 594 
Semenza GL (2000) HIF -1: mediator of physiological and pathophysiological responses to 
hypoxia. J Appl Physiol 88: (4):1474- 1480  
Tonelli M, Wiebe N, Culleton B, et al. (2006) Chronic kidney disease and mortality risk: a 
systematic review. Am Soc Nephrol 17: (7):2034- 2047 
USRDS (2008) U.S. Renal Data System, USRDS 2008 Annual Data Report: Atlas of End- Stage 
Renal Disease in the United States. United States Renal Data 
System:(http://www.usrds.org/atlas.htm)  
USRDS (2009) U.S . Renal Data System, USRDS 2009 Annual Data Report: Atlas of End- Stage 
Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2009. United States Renal Data System:(http://www.usrds.org/atlas.htm)  
Van Wyck DB et al. (2010) A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis -dependent CKD. Kidney Int 68:2846–2856. 
Wang GL, Jiang BH, Rue EA, Semenza GL (1995) Hypoxi a-inducible factor 1 is a basic -helix -
loop- helix -PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A 92: 
(12):5510- 5514  
Warnecke C, Zaborowska Z, Kurreck J, et al. (2004) Differentiating the functional role of hypoxia -inducible factor (HIF)- 1alpha and HIF -2alpha (EPAS -1) by the use of RNA 
interference: erythropoietin is a HIF -2alpha target gene in Hep3B and Kelly cells. The FASEB 
Journal 18: (12):1462- 1464 
Winearls CG, Oliver DO, Pippard MJ, Reid C, Downing MR, Cotes PM (1986) Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 2: (8517):1175- 1178  
Zhang Y, Thamer M, Stefanik K, Kaufman J, Cotter DJ (2004) Epoetin requirements predict mortality in hemodialysis patients. Am J Kidney Dis 44: (5):866- 876 
Roxadustat  Protocol FGCL -4592 -059 Amendment 2  
FibroGen, Inc.  57 Confidential  
    APPENDIX A.  SCHEDULE OF STUDY ASSESSMENTS  
Roxadustat  Protocol FGCL -4592 -059 Amendment 2  
FibroGen, Inc.  58 Confidential  
     Treatment Period a Follow -Up 
Period b 
 Baseline 
(Week 1)  Weekly 
Visits  
(Weeks 1- 4) 
(± 3 days)c Every 
2 weeks 
(Weeks 6- 24) 
(± 3 days)  Every 
4 weeks 
(± 3 days)  Every 12 weeks 
(± 7 days)  Every 
24 weeks 
(± 7 
days)  Termination Visit or ET 
(± 3 days)  
Written informed consent  X        
Eligibility criteria  X       
Dispense study drug  X X X X X X  
Physical examination  X    X X X 
Weight d X e    X X X 
BP, HR, respiratory rate  X X X X X X X 
12-lead ECG  X e     X X 
hCG test for female subjects of child bearing 
potential only  X e      X 
CBC with WBC differential and reticulocyte 
count  X X X X X X X 
Fasting f serum chemistry (including LFTs, lipid 
panel, glucose)  X   X X X X 
Serum iron, ferritin, transferrin (or TIBC) , TSAT  X   X X X X 
Special labs (CHr, hepcidin, hs -CRP, plus 
exploratory biomarkers)g X e     X X 
Dose adjustment review    X X X X  
Quality -of-life questionnaire (FACT -An) X e     X X 
AE reporting  X X X X X X X 
Concomitant medication  X X X X X X X 
Abbreviations:  AE = adverse event; BP  = blood pressure; CBC  = complete blood count; CHr  = reticulocyte hemoglobin content; CRP  = C-reactive protein; 
ECG  = electrocardiogram; ET = Early Termination; FACT -An = . Functional Assessment of Cancer Therapy -Anemia; hCG  = human c horionic gonadotropin; HR  = heart 
rate; LFT = liver function test; TIBC  = total iron binding capacity; TSAT  = transferrin saturation; WBC  = white blood cell.  
a Subjects are to be dosed for up to 260 weeks (5 years)  or 52 weeks if newly enrolled in Amendment 2 
b Follow up Visit is 4 weeks after last dose of study treatment  
c Weekly visits are only for subjects newly initiated to roxadustat  until Hb stabilizes  
d Use dry weight in HD subjects  
e To be performed prior to study drug administration.  The End-of-Study assessments in the previous  roxadustat study may be used for assessments if they were 
completed within 4 weeks prior to study drug administration.  
f Fasting is preferred, if possible 
g Only collect for subjects who have a baseline special lab collected during prior  roxadustat study.   
Roxadustat  Protocol FGCL -4592 -059 Amendment 2  
FibroGen, Inc.  59 Confidential  
    APPENDIX B.  DOSING FOR SUBJECTS PREVIOUSLY TREATED WITH 
PLACEBO  
Subjects who received placebo in their previous study will receive roxadustat according to their weight as described in the table below.  
If treatment assignment is blinded at the time of enrollment, the subject has been on a  stable 
dosing regimen for at least 2 months and if the last dose is lower than the starting doses 
described in Appendix B , the subject may continue  on the current dosing regimen 
Weight -Based Doses for Subjects Previously Treated with Placebo  
Low W eight  
(< 60 kg)  Medium W eight  
(>60 to 90 kg)  Heavy Weight  
(>90 kg)  
70 mg  100 mg  150 mg  
 
Roxadustat  Protocol FGCL -4592 -059 Amendment 2  
FibroGen, Inc.  60 Confidential  
    APPENDIX C.  DOSE ADJUSTMENT GUIDELINES FOR ROXADUSTAT  
All dose adjustments should be based on Hb values using a point -of-care device, such as 
HemoCue® or CritLine®. In the event that the central lab Hb value of the site visit is 
significantly different and the dose adjustment decision based on the HemoCue® / CritLine® value is being re - considered, the Medical Monitor should be contacted, if possible. 
Dose adjustment reviews will occur on Week 4, and at intervals of every 4 weeks thereafter 
(Weeks 8, 12, 16, etc.), except in the event of excessive hematopoiesi s, in which case doses may 
be adjusted at any time. In such cases, dose adjustment reviews are resumed at 4- week intervals. 
For example, if the subject’s Hb increases > 2.0 g/dL from Week 1 to Week 3, the subject’s dose 
is reduced by one dose step at Week 3. The next dose adjustment review should occur 4 weeks later at Week 7. If the dose adjustment interval falls on a non- study visit week (starting Week 4), 
the dose adjustment review should be performed at the next scheduled study visit if a dose adjustmen t was not required at the previous visit. For example, if a subject’s visit is scheduled 
for Weeks 6 and 8, and the dose adjustment would occur at Week 7, then the dose adjustment should be evaluated at the Week 8 visit. 
All subjects will be dosed orally T IW during the Treatment period. During the course of the 
study, the dose and the dosing frequency may be changed to optimize efficacy and tolerability 
based on the clinical judgment of the investigator and study medical monitor. If a subject requires < 20 mg TIW (ie, < 60 mg per week) to maintain the target Hb level, the dosing frequency should be reduced in a step- wise fashion eg, TIW to BIW, BIW to QW, QW to Q -2 
Week etc. The Medical Monitor should be notified as soon as possible of such dose change. The maximum roxadustat dose is 3.0 mg/kg per dose or 400 mg (whichever is lower).  
The following scenarios are defined as “excessive hematopoiesis”;  
Hb increases by > 2.0 g/dL at any time within a 4 week period: reduce the dose by one dose step. 
Hb reaches or exceeds 13 g/dL: hold dosing, check Hb weekly. Resume dosing when Hb 
< 12.0 g/dL (for US subjects central lab Hb value preferred), at a dose that is reduced by two dose steps. 
For subjects on prolonged dose -hold, with stable (not dropping) Hb, PI may use di scretion to 
schedule less frequent visits. Anytime Hb is assessed via HemoCue®/CritLine®/local lab, a central lab Hb should be obtained as well.  
Given the complexity in roxadustat dose adjustments, and the need to take into account the various clinical par ameters in roxadustat dose titration, one would not consider it a protocol 
deviation when study subjects are dosed based on their clinical circumstances, whether or not it is concordant with the roxadustat dose adjustment guidelines unless it was related t o “excessive 
hematopoiesis” (eg,,Hb ≥ 13 g/dL, requiring a dose hold)) or “Overdose” (prescribed >3.0 mg/kg per dose or 400 mg per dose whichever is lower)  
Roxadustat  Protocol FGCL -4592 -059 Amendment 2  
FibroGen, Inc.  61 Confidential  
    Roxadustat Dose Adjustment Rules  
Change in Hb  
from 4 weeks  
earlier (g/dL)  
 Hb < 10.5  
g/dL  Hb 10.5 to 11.9  
g/dL  Hb 12.0 to 12.9  
g/dL  Hb ≥ 13.0  
g/dL  
< -1.0 ↑ ↑ No change  
Hold,  then resume dosing when:  
Hb < 12 g/dL,  at a dose that is  
reduced by two dose  steps  
 
Subjects are to return weekly  to 
monitor Hb until dosing can be 
resumed**  -1.0 to 1.0  ↑ No change  ↓ 
> 1.0 No change  ↓ ↓ 
Dose Adjustment for Excessive Hematopoiesis:  
At any time during the Treatment Period if Hb increases  by 
>2.0 g/dL within  4 weeks, the dose should be reduced by  one dose  step.  
** For subjects on prolonged  dose- hold, with  stable (not  dropping)  Hb, PI may use discretion to schedule les s 
frequent visits. Anytime Hb is assessed via HemoCue®/CritLine®/local labs, a central lab Hb should be 
obtained as well  
 
Dose Increases and Reductions:  
Dose increases (↑) and reductions (↓) are preset to dose steps.  The dose steps are as follows:  
20, 40, 50, 70, 100,  150, 200, 250, 300, and 400 mg.  
Example: A dose increase at  a dose of 70 mg  results in 100 mg as the new dose. A dose reduction at  a dose 
of 150 mg results in 100 mg as the new  dose.  
Note: Maximum  dose capped at 3.0 mg/kg per dose or 400  mg, whichever is lower.  
 
*Transition  from  Correction  to Maintenance  Phase will occur  once  the central  laboratory  Hb value is ≥ 
11 g/dL  and ≥ 1 g/dL  from  baseline  
 